Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 1 of 124  
 THOMAS JEFFERSON UNIVERSITY  
Sidney Kimmel Cancer Center  
 
Nivolumab plus Weekly Carboplatin and Paclitaxel as 
Induction in Resectable Locally Advanced Head and 
Neck Cancer  
 
Principal Investigator:  [INVESTIGATOR_20942] M Johnson, MD PhD  
Department of Medical Oncology  
[ADDRESS_700013]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11119] 
Co-Principal 
Investigator(s):  David Cognetti, MD  
Department of Otolaryngology  
[ADDRESS_700014],6th Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11120]  
 
Athanassios Argiris, MD PhD  
Department of Medical Oncology  
[ADDRESS_700015]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11119] 
Abington PI:  [INVESTIGATOR_537477] J. Nordlinger, MD  
[ADDRESS_700016],  
Abington, PA [ZIP_CODE]  
Phone: [PHONE_11121]  
Fox Chase Cancer 
Center  
Principal Investigator:  [INVESTIGATOR_537478], MD  
[ADDRESS_700017] 
Philadelphia, PA [ZIP_CODE]  
Co-Investigator(s):  Rita Axelrod, MD  
Department of Medical Oncology  
[ADDRESS_700018]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11119]  
 Avnish Bhatia, MD  
Department of Medical Oncology  
[ADDRESS_700019]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11119] 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700020], Room G301N  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11122]  
 
Joseph Curry, MD  
Department of Otolaryngology  
[ADDRESS_700021],6th Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11120]  
 
Adam Luginbuhl, MD  
Department of Otolaryngology  
[ADDRESS_700022],6th Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11120]  
 
Christopher Fundakowski, MD  
Department of Otolaryngology  
[ADDRESS_700023],6th Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11120]  
 
Elizabeth Cottrill , MD  
Department of Otolaryngology  
[ADDRESS_700024],6th Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11123]  
 
Andrew Yampolsky, DDS, MD  
Department of Oral and Maxillofacial Surgery  
[ADDRESS_700025] Floor  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11124]  
 
Pathology:  
Charalambos Solomides, MD  
Madalina Tuluc, MD  
Department of Pathology  
Main Building, Room [ADDRESS_700026]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11125]  
 
Correlative Sciences:  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700027]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11126]  
 
Bo Lu, MD PhD  
Department of Radiation Oncology  
[ADDRESS_700028], Room G301N  
Philadelphia, PA [ZIP_CODE]  
[PHONE_11122]  
 
Grace Lu Yao, PhD  MPH  
Department of Medical Oncology  
Bluemle  
[ADDRESS_700029], Rm 812 
Philadelphia, PA [ZIP_CODE]  
[PHONE_11127]  
Statistician:  Benjamin Leiby, PhD  
Department of Pharmacology and Experimental Therapeutics  
[ADDRESS_700030]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_8852]  
Funding Supporter and 
Nivolumab Provider  Bristol -Myers Squibb  
IND/IDE Holder:  Jennifer Johnson, MD, PhD  
IND/IDE Number:  [ADDRESS_700031]:  Nivolumab  
Protocol IDs:  CA209 -9FT 
JeffTrial # [ZIP_CODE]  
PRC # 2017- 100 
IRB Control # 17P.513  
 
Version  Number : Version Date:  
2.0 2017 -05-02 
2.1 2017 -11-03 
3.0 2017 -11-16 
3.1 2018 -06-29 
3.2 2018 -10-26 
3.3 2019 -03-15 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 4 of 124  
 4.0 2019-04-09 
5.0 2019 -11-05 
 
CONFIDENTIAL  
This document is confidential and the property of THOMAS JEFFERSON UNIVERSITY.  
No part of it may be transmitted, reproduced, published, or used by [CONTACT_137005].  
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700032] of Abbreviations  ..................................................................................................................12 
Study Summary  ........................................................................................................................14 
1 Introduction  .........................................................................................................................17 
1.1 Background Information  ..............................................................................................17 
1.2 Rationale for the Proposed Study  ...............................................................................25 
1.3 Correlative Studies  ......................................................................................................30 
1.4 Potential Risks and Benefits  .......................................................................................32 
1.4.1  Potential Risks .........................................................................................................32 
1.4.2  Benefits  ...................................................................................................................35 
2 Study Objectives  .................................................................................................................35 
2.1 Objectives  ...................................................................................................................35 
2.1.1  Primary  ....................................................................................................................35 
2.1.2  Secondary  ...............................................................................................................35 
2.1.3  Exploratory  ..............................................................................................................35 
2.2 Endpoints/Outcome Measures  ....................................................................................36 
2.2.1  Primary  ....................................................................................................................36 
2.2.2  Secondary  ...............................................................................................................36 
2.2.3  Exploratory  ..............................................................................................................36 
3 Study Design  ......................................................................................................................37 
3.1 Characteristics  ............................................................................................................37 
3.2 Number of Participants  ...............................................................................................38 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 6 of 124  
 3.3 Duration of Therapy  ....................................................................................................38 
3.4 Duration of Follow Up ................................................................................................. 39 
3.5 Study Timeline  ............................................................................................................39 
3.5.1  Primary Completion  ................................................................................................. 39 
3.5.2  Study Completion ....................................................................................................39 
4 Study Enrollment and Withdrawal  .......................................................................................39 
4.1 Eligibility Criteria  .........................................................................................................39 
4.1.1  Inclusion Criteria  ......................................................................................................39 
4.1.2  Exclusion Criteria  ....................................................................................................40 
4.2 Gender/Minority/Pediatric Inclusion for Research ........................................................[ADDRESS_700033] Storage and Stability  ..................................................................................46 
5.3 Dosage, Preparation, and Administration  ....................................................................47 
5.4 Dose Modifications and Dosing Delays  .......................................................................48 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700034] Administration ........................57 
5.7 Concomitant Medications/Treatments  .........................................................................57 
5.8 Dietary Restrictions  .....................................................................................................58 
6 Study Schedule ..................................................................................................................58 
6.1 Pretreatment Period/Screening ..................................... Error! Bookmark not defined.  
6.2 Enrollment/Baseline  ...................................................... Error! Bookmark not defined.  
6.[ADDRESS_700035]-Surgical/Follow -Up..............................................................................................[ADDRESS_700036]-Treatment/Follow -Up ..........................................................................................64 
6.7 Withdrawal Visit/Discontinuation of Therapy  ...............................................................64 
6.8 Surgery  .......................................................................................................................64 
6.9 Radiation ....................................................................................................................64 
7 Study Procedures and Evaluations  .....................................................................................65 
7.1 Study Procedures/Evaluations  ....................................................................................65 
7.2 Laboratory Procedures/Evaluations  ............................................................................66 
7.2.1  Clinical Laboratory Evaluations  ...............................................................................66 
7.2.2  Special Assays or Procedures  .................................................................................66 
7.2.3  Specimen Preparation, Handling, and Stora ge ........................................................67 
7.2.4  Specimen Shipment  ................................................................................................67 
8 Evaluation of Safety  ............................................................................................................67 
8.1 Specification of Safety Parameters  .............................................................................67 
8.1.1  Unanticipated Problems  .......................................................................................... 67 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700037] Result Abnormalities  .........................................................................75 
8.6 Overdose  ....................................................................................................................75 
8.7 Potential Drug Induced Liver Injury (DILI)  ................................................................... 76 
8.8 Halting Rules  ..............................................................................................................76 
9 Study Oversight  ..................................................................................................................76 
10 Clinical Site Monitoring and Auditing ..............................................................................76 
11 Statistical Considerations  ...............................................................................................77 
11.1 Study Hypotheses  .......................................................................................................77 
11.2 Analysis Plans  ............................................................................................................77 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 9 of 124  
 11.3 Interim Analyses and Stoppi[INVESTIGATOR_1869] ..........................................................................78 
11.3.1  Safety Review  ......................................................................................................78 
11.3.2  Efficacy Review ...................................................................................................78 
11.4 Sample Size Considerations  .......................................................................................79 
11.4.1  Replacement Policy  .............................................................................................79 
11.4.2  Accrual Estimates  ................................................................................................79 
11.5 Exploratory Analysis  ...................................................................................................79 
12 Source Documents and Access to Source Data/Documents  ..........................................79 
13 Quality Control and Quality Assurance  ...........................................................................79 
14 Ethics/Protection of Human Participants  .........................................................................[ADDRESS_700038] ...........................................................................................80 
14.3 Informed Consent Process  ..........................................................................................80 
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  ..........................[ADDRESS_700039] Keepi[INVESTIGATOR_007] ...............................................................................81 
15.1 Data Management Responsibilities  .............................................................................81 
15.2 Data Capture Methods  ................................................................................................81 
15.3 Types of Data  .............................................................................................................81 
15.4 Study Records Retention  ............................................................................................ 81 
15.5 Protocol Deviations  .....................................................................................................82 
16 Study Finances  ...............................................................................................................82 
16.1 Funding Source  ..........................................................................................................82 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700040]  .......................................................................................................82 
16.3 Participant Stipends or Payments  ...............................................................................82 
17 Publication and Data Sharing Policy  ...............................................................................82 
18 Literature References  .....................................................................................................83 
Appendices  ...............................................................................................................................87 
APPENDIX A: SCHEDULE OF EVENTS  ..................................................................................88 
APPENDIX B: ECOG PERFORMANCE STATUS  .....................................................................92 
APPENDIX C: AJCC 8TH EDITION STAGING SYSTEM  ...........................................................94 
APPENDIX D: MANAGEMENT ALGORITHMS ....................................................................... 105 
APPENDIX E: NCI PRO -CTCE ITEMS  ................................................................................... 114 
APPENDIX F: UNATICIPATED PROBLEM FORM  .................................................................  121 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 11 of 124  
 Signature [CONTACT_509288], and 
provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.  
Principal Investigator:  
[INVESTIGATOR_14586]:   Date:   
Name:   
[CONTACT_1641]:    
Statement of Compliance  
This study will be conducted in accordance with the International Conference on Harmonisation 
guidelines for Good Clinical Practice (ICH E6), the Code of Federal Regulations on the 
Protection of Human Subjects (45 CFR Part 46), and Thomas Jefferson University research 
policies  
 
  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700041] of Abbreviations  
AE Adverse Event/Adverse Experience  
BOR  Best Overall Response 
CFR Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CONSORT  Consolidated Standards of Reporting Trials  
CR Complete response  
CrCl Creatinine Clearance  
CRF Case Report Form  
CRO  Clinical Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
CTO  Clinical Trials Office  
CTOC  Clinical Trials Oversight Committee  
DSMC  Data and Safety Monitoring Committee  
DSMP  Data and Safety Monitoring Plan 
FDA Food and Drug Administration 
FWA  Federalwide Assurance 
GCP  Good Clinical Practice  
GWAS  Genome -Wide Association Studies  
HIPAA Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IDE Investigational Device Exemption 
IND Investigational New Drug Application 
IRB Institutional Review Board 
IRC Imaging Response Criteria 
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_425553] s) 
NCI National Cancer Institute  
NIH National Institutes of Health 
OAR  Organ At Risk  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 13 of 124  
 OHRP  Office for Human Research Protections  
ORR Objective Response Rate 
OS Overall Survival  
PFS Progression Free Survival  
PHI Protected Health Information 
PI [INVESTIGATOR_537479]/Serious Adverse Experience 
SCCHN  Squamous Cell Carcinoma of the Head and Neck  
SDS Safety Data Sheet (formerly MSDS; Material Safety Data Sheet)  
SKCC  Sidney Kimmel Cancer Center  
SOP Standard Operating Procedure  
TJU Thomas Jefferson University  
UAP Unanticipated Problem  
ULN Upper Limit of Normal  
  
  
  
  
  
  
  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 14 of 124  
 Study Summary  
Title:  Nivolumab plus Weekly Carboplatin and Paclitaxel as Induction in Resectable 
Locally Advanced Head and Neck Cancer  
 
Précis:  Patients with locally advanced squamous cell carcinoma of the head and 
neck who are candidates for curative intent surgery will be treated with a 
combination of induction weekly carboplatin and paclitaxel plus nivolumab, to 
assess the rate of pCR a t the primary tumor over historical control with 
induction chemotherapy alone.  
 
Objectives:  
 Primary:  
The primary objective of the study is to estimate pathologic complete response (pCR) at the primary site in patients with newly diagnosed and 
untreated Stage III- IVA SCCHN of the Oral Cavity, Oropharynx, Larynx, and 
Hypopharynx   treated with Nivolumab, paclitaxel, and carboplatin in addition 
to standard chemotherapy.  
 
Secondary:  
• Safety  
• Complete Pathologic Response at all sites of disease 
• Major pathologic response rate at primary site 
• Overall Clinical Response Rate  
• Clinical Complete Response Rate  
• 1 year PFS.  
• Overall survival.  
 Exploratory:  
• To explore whether PDL1 expression is associated with treatment 
response  
• To explore whether there is a net change in the Th1/Th2 ratio ( IFN- γ , 
IL-4, IL10, etc.) or cell subset frequencies (M2 monocytes, myeloid-
derived suppressor cells, etc.) within a patient’s peripheral blood 
either at baseline or in response to treatment is associated with 
treatment response  
• To expl ore whether exosomes or other immune related serum 
biomarkers change after combination therapy.  
• To explore the predictive value of serial cell free DNA levels and response  
 
Population:  Patients with newly diagnosed and untreated stage III -IVA SCCHN of the : 
Oral cavity, Oropharynx, Larynx, and Hypopharynx.  
 
Phase:  II 
 
Number of 
Sites:  • 3: Thomas Jefferson University, [LOCATION_003]  (lead site) , Fox Chase Cancer 
Center , 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 15 of 124  
 •  
• Abington Memorial Hospi[INVESTIGATOR_537480]:  An optimal Simon two -stage design will be used.  The null hypothesis is that 
the true pathologic complete response rate at the primary tumor site is ≤ 0.[ADDRESS_700042] the alternative that it is >0.20. After testing the 
regimen on [ADDRESS_700043] stage, the trial will be terminated if 3 or  
fewer respond. If the trial goes on to the second stage, a total of 37 patients will be studied. If the total number responding is less than or equal to 10, the regimen is rejected.  This design yields a type I error rate of 9.5% and power 
of 90% when the  true response rate is 0.40. It has a 55% probability of 
stoppi[INVESTIGATOR_4428]. The pathologic complete response rate and its associated score 95% confidence interval will be estimated using the methods of Tsai et 
al (2008).
20   
 
Description 
of 
Intervention:  This is a phase II trial looking at the combination of weekly carboplatin plus 
paclitaxel to which nivolumab is added as induction therapy prior to planned 
surgery for the definitive management of locally advanced squamous cell 
carcinomas of the head and neck . 
 Treatment Plan:  
Induction Nivolumab + Carboplatin + Paclitaxel:  
• Nivolumab 240mg every 2 weeks x 3 doses (last dose at least 3 weeks before surgery)  
• Carboplatin AUC 2 weekly x 6 doses (last dose at least 2 weeks before surgery)  
• Paclitaxel 100 mg/m
2 x 6 doses (last dose at least 2 weeks before 
surgery)  
 
Study 
Duration:  38 months  
Participant  
Participation 
Duration:  8 months  
Estimated 
Time to 
Complete 
Enrollment:  30 months  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 16 of 124  
 Schematic of Study Design:  
Prior to  
Enrollment  
(Day -28 to  
Day -1) 
   
Visit 1  
Day 0  
 
  
 
Visit 2 
Week 1 Day 1  
  
  
 
Visit 3 & 4  
Days 15 & 29  
(± 4 days)  
 
 
 
Visit 5 
Day 50 
(± 4 days)  
  
 
Visit 6  
Day 57 
(± 7 days)  
 
 
 
 
 
 Obtain informed consent. Screen potential subjects by [CONTACT_179912]; obtain history and physical, document  
Perform baseline assessments.  
Confirmation of cancer histology and p16 status; IHC for PDL1 expression on 
initial biopsy; Dra w blood for serologic assessment for Th1/Th2 ratio, exosomes.  
Administer initial study intervention.  
Day of surgery: 1) CT scan preop  2) Draw blood assessment for Th1/Th2 ratio, 
exosomes . 3) History & Physical exam 4)  Safety assessment  
 Safety assessments Day 15 & 29  
Day 29 Draw blood for s erologic assessment for Th1/Th2 ratio, exosomes .  
Continuous Assessment of SAEs 
and the Recurrence  
     Nivolumab 240mg x q 2wk x 3 
Carboplatin AUC 2 q wk x 6  
Paclitaxel 100 mg/m2 q wk x 6  
 
1) Postop evaluation and exam, 2) Draw blood for Th1/Th2 ratio, exosomes. 3) 
Wound assessment  
Postoperative Standard of Care (Postoperative therapy as per the HNC tumor 
board recommendations).  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 17 of 124  
 1 Introduction  
1.1 Background Information  
Over 58,000 new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed 
leading to more than 1300 deaths each year in the [LOCATION_002]1. Oropharyngeal cancer remains 
one of the few cancers that is on the rise in our population with an exceptional rate of increase 
per year1. The prognosis of head and neck cancer is highly variable based on subsite location 
and stage with an overall survival of 63% and with advanced stage disease with survival rates of 38-62%.
1 Earlier stage cancers are often treated with single modality therapy of either surgery or 
radiation, with advanced stages needing multimodality therapy including platinum based chemoradiotherapy regardless of surgery. Moreover, for early stage tumors and for those with 
local involvement of lymph nodes, resection is the cornerstone of therapy.  Approximately 50% of 
head and neck cancer patients have primary surgery. More locally advanced cancers that are 
resected will also often require either ad juvant radiation therapy or chemoradiation to decrease 
local and regional recurrence rates. Surgical resections can cause considerable morbidity in the more locally advanced cases including a loss of swallowing and larynx function. Post -operative 
radiation can add further long term morbidity. In advanced local disease, after surgery and 
postoperative therapy, the current standard, 5 year survival rates are on the order of 50%.  Patients with resectable locally advanced squamous cell carcinoma of the head and neck 
(SCCHN) remain at high risk for loco -regional and distant recurrence despi[INVESTIGATOR_537481]/high risk features.
2 About half of patients with advanced local oral cavity cancer will 
die of either loco -regional and/or distant metastases or a second primary cancer. [ADDRESS_700044] remains surgery followed by [CONTACT_4171], radiation or chemo -radiation depending on operative findings, the patient’s condition and 
assessed level of risk of recurrence. However, given the substantial risk of recurrence and death after these interventions and the frequent sustained morbidity of the definitive procedures, 
presurgical induction therapy has been investigated.   
Results from two phase III trials comparing induction chemotherapy followed by [CONTACT_537499] (figure 1 ). 
4,5 
 
  
 
 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 18 of 124  
 Figure 1.  
 
In the conducted by [CONTACT_537500]., patients with clinical stage III -IVA OSCC were randomized to 
immediate surgery or 2 cycles of TPF followed by [CONTACT_537501]. 4 In the PF induction study by [CONTACT_537502]., patients with clinical stage II -IV 
(T2(>3cm) -T4, N0 -N2) OSCC were randomized to induction 3 cycles of PF or immediate surgery. 
5   Postoperative radiation was given to patients in either arm only in high risk patients.    
In the study by [CONTACT_537500]., patients had clinical stage III -IVA OSCC of whom 43% had clinical 
stage N0 stage with all patients having at least T1 (figure 2). In the study by [CONTACT_537503], resectable clinical stages II -IV were eligible with a requirement that primary lesions be T2 > 3cm. About 57% 
had no clinical evidence of lymph node involvement at baseline (figure 3)  
The percent of patients assigned each arm across the 2 studies who received the planned surgery and reasons for not getting the surgery are summarized here. A total of 256 patients were 
randomized in the TPF study of whom 124/128 in the induction arm received presurgical TPF and 
118/124 (95%) of these had surgery compared to 127/128 (99%) randomized to surgery without 
induction. Of the 6/[ADDRESS_700045] surgery, 3/124 (2.4%) died during 
induction not felt to be from the TPF and 3 refused surgery (2 received radiation and 1 refused 
both surgery and radiation). Toxicities were modest with 6.6% having grade 3 hematologic toxicity 
and 0.8% and 1.6% having grade 3 diarrhea or febrile neutropenia respectively.  
In the PF study, a total of 198 patients were randomized of whom 98/99 in the PF arm were evaluable and 96/99 completed follow -up. Of the evaluable patients on the PF arm, 92/98 (94%) 
received surgery compared to the 99 patients randomized to the control arm in which 97/99 were evaluable ([ADDRESS_700046] after randomization) and 97/97 evaluable patients had surgery. O f the 6/98 (6%) 
on PF who did not have surgery, 3 died from toxicity, another 1 had an MI, one developed distant 
metastases and 1 refused. Two other patients had surgery on their primary but no planned lymph 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 19 of 124  
 node dissection but receiving radiation to the neck. Toxicities were more pronounced on this study 
compared to the TPF study with 25.5% and 11.2% of patients having at least on grade 3 or 4 
toxicity respectively though only 1% of patients had a non- hematologic toxicity of grade 4, 
mucositis (and 3 patients had grade 5 toxicity).   
Figure 2  
 
 
 
 
 
Figure 3  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 20 of 124  
  
Clinical responses to induction were seen in a high percentage of patients in both studies (figure 
4). In the TPF induction study by (Zhong et al.), 122/124 (98.4%) patients received both cycles 
(2/124) just 1 cycle with a RR of 100 /124 (81%) of whom 10/124 (8%) were CRs with only 1 
patient (0.8%) with PD. In the PF study (Licitra et al.), 85/98 (87%) received at least 2 of the 3 planned courses. The authors reported the responses on these 85 with RR of 70/85 (82%) of 
whom 28/85 (33%) were CRs at all sites  of disease with PD not reported though [ADDRESS_700047] induction surgery.  
Pathologic responses were evaluated as pPD, pSD, pPR, pMRT (microscopic residual tumor) and CR variously at the primary site and LN and the primary site alone (figure 4). pMRT was 
described as scattered foci of a few tumor cells in the paper by [CONTACT_537502]. and more specifically as <10% viable tumor cells in the TPF induc tion study (Zhong et al.). The latter more precise 
definition underlay their later analyses of overall survival (OS) in those patients who had at least a pMRT. Of 124 patients who received induction TPF, a favorable pathologic response defined 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 21 of 124  
 as patients who had either pMRT or pCR, was seen in 27% for both primary and nodal disease 
with 13% of these having a pCR. In the study by [CONTACT_537502]., patients who received induction PF 
had a 33% pFR of whom 27% had a pCR. They also reported pFR of 45% at the prim ary site of 
whom 27% were pCR.   
Figure 4.  
 
The induction arm did not yield increased OS in either study (figure 5, 6) though the authors of the TPF induction study conclude that failure to achieve a statistical improvement in OS may represent a type II error from a potentially underpowered study. They also observed that only [ADDRESS_700048] limited the level of efficacy (Zhong, JCO, 2013). However, when evaluating OS among 
patients who had a pFR in the TPF induction study, there was statistical improved OS compared 
to patients whose tumors did not have a pFR and compared to the patients who had no induction 
therapy (figure 7). Interestingly, though the patients who did not have a pFR did not have a 
superior survival, they had a numerically comparable OS compared to the patients who had no induction TPF. In the paper by [CONTACT_537502]., the subset of patients who achieved a pCR had a 
statistically improved DFS (p=0004).   
The authors of the TPF study did not observe increased postoperative morbidity including flap failure (2 in each arm), postoperative hematoma (1 in each arm), and a chylous fistula after neck 
dissection in on patient in the experimental arm. Likewise, radiation toxicities were similar between the arms.  In the PF induction study, there were statistically fewer mandibulectomies in 
the experimental arm (31% vs. 52% with a 21% difference (95% CI 7 -34%)). There were also 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 22 of 124  
 fewer patients in the experimental  arm who received radiation given decrease in stage and risk 
factors with 33% vs. 46% with a 13% difference (95% CI 0 -27%). This would be expected to 
reduce long term morbidity.   
Thus, in summary, the two phase III induction studies in stage II -IVA surgic al OSCA were 
generally well tolerated, did not prevent surgery from toxicity or progression, did not lead to excess 
post-operative complications, and showed hints of decreased post -operative and post radiation 
morbidity compared to the control arm.  In addition, there were some intriguing survival signals seen in the TPF induction study by [CONTACT_537500]. In both studies, pFR or pCR predicted improved 
OS compared to the non -induction immediate surgery controls.   
Figure 5
 
 
 
    
Figure 6  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 23 of 124  
  
Figure 7  
 
Figure 8  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700049] ipi[INVESTIGATOR_537482].7 Further work with single agent pembrolizumab demonstrated 20- 25% effectiveness 
with low rate of grade 3 or 4 toxicity in patients with recurrent/metastatic HNSCC. Since that time additional checkpoint inhibitors have been approved i.e. pembrolizumab for melanoma and 
nivolumab for non -small lung cancer and renal cancer.  
Recently immunotherapy has become a promising new treatment option for recurrent head and neck squamous cell carcinomas.
[ADDRESS_700050] randomized trial to show improved 
overall survival for platinum -refractory recurrent or metastatic HN -SCC patients using nivolumab 
compared to single -agent chemotherapy of the investigator’s choice.8,[ADDRESS_700051] a poor 
prognosis and average survival less than 6 months. After failing platinum -based therapy for 
recurrent HNSCC within 6 months, patients were randomized 2:1 to receive nivolumab (a PD -1 
inhibitor) or a single- agent chemotherapeutic or biological agent of the investigator’s choice, 
which included methotrexate, docetaxel, or cetuximab. At interim analysis, there was already a 
30% reduction in risk of death with nivolumab versus standard therapy. Regardless of PD -L1 
status or HPV p16 status, median overall survival was 7.[ADDRESS_700052] igator’s choice of therapy. Further, HPV+ patients and patients 
with PD- L1 ≥1% had an even greater benefit and significantly longer overall survival with 
nivolumab. These patients also experienced an improvement in their quality of life across multiple measures.  
The impressive results of T cell -directed immunotherapi[INVESTIGATOR_537483] a 
subset of patients enjoys long- lasting remissions after single modality immune checkpoint 
therapy. This circumstance has reinvigorated interest in under standing how systemic and local 
factors may interfere with the function of T cells and other effector immune cells critical to tumor 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 25 of 124  
 control. It is now widely accepted that immunosuppressive cells and factors in the tumor 
microenvironment (TME) contribute to suboptimal responses to immune checkpoint 
therapeutics. Thus, there is interest in testing combinatorial approaches to “boost” the responses seen with nivolumab monotherapy.  
Nivolumab 
Nivolumab (Opdivo) is in clinical development for the treatment of subjects with melanoma, non -
small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck carcinoma and 
other tumors (e.g., gastric cancer, glioblastoma multiforme, hodgkins lymphoma, small cell lung 
cancer). Opdivo as monotherapy has been approv ed in the US in multiple indications, including, 
unresectable or metastatic melanoma and disease progression following ipi[INVESTIGATOR_164] a 
BRAF inhibitor, if BRAF V600 mutation positive; previously untreated patients with BRAF wild-
type unresectable or metast atic melanoma; NSCLC with progression on or after platinum -based 
chemotherapy; and advanced renal cell carcinoma who have received prior anti -angiogenic 
therapy. The combination of nivolumab and ipi[INVESTIGATOR_537484]. Patients with recurrent or 
metastatic SCCHN have poor prognosis and experience limited survival benefit with standard of 
care therapi[INVESTIGATOR_014]. In patients with recurrent or metastatic SCCHN who progress with platinum  
chemotherapy, nivolumab demonstrated prolonged survival benefit over standard of care in the Checkmate [ADDRESS_700053] line treatment 
setting, nivolumab in combination with ipi[INVESTIGATOR_537485]209651 clinical study.   
Mechanism of action  
Nivolumab (also referred to as BMS -936558 or MDX1106) is a human monoclonal antibody 
(HuMAb; immunoglobulin G4 [IgG4]- S228P) that targets the programmed death- 1 (PD 1) cluster 
of differentiation 279 (CD279) cell surface membrane receptor. PD -1 is a negative regulatory 
molecule expressed by [CONTACT_93247] T and B lymphocytes33. Binding of PD -1 to its ligands, 
programmed death– ligands 1 (PD -L1) and 2 (PD -L2), results in the down- regulation of 
lymphocyte activation. Inhibition of the interaction between PD -1 and its ligands promotes 
immune responses and antigen -specific T -cell responses to both foreign antigens as well as 
self-antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced 
using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.  
1.2 Rationale for the Proposed Study  
Patients with resectable locally advanced squamous cell carcinoma of the head and neck (SCCHN) remain at high risk for loco -regional and distant recurrence despi[INVESTIGATOR_537481]/high risk features.
2 About half of patients with advanced local oral cavity cancer will 
die of either locoregional and/or distant metastases or a second primary cancer.[ADDRESS_700054] -operative radiotherapy in patients did not 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 26 of 124  
 show improved overall survival using TPF, and PF r espectively.4 However, there were high  
response rates and patients with pathological complete response (pCR) had better PFS and 
OS.4 Induction chemotherapy may result in major tumor responses that reduce surgical 
morbidity and decrease the likelihood of positive surgical margins and potentially reduce postoperative radiation therapy.
6 Thus, induction with TPF or PF did not reduce efficacy but 
showed evidence of reducing morbidity and afforded the chance to identify at surgery a subset 
of patients with pCR who had excellent prognosis.   
Use of weekly carboplatin/paclitaxel may be an alternative to TPF and offers an active backbone regimen to incorporate novel therapi[INVESTIGATOR_014].
[ADDRESS_700055] -line advanced non -squamous NSCLC, 
patients randomized to carboplatin plus pemetrexed plus pembrolizumab showed improved 
response and time to progression compared to chemotherapy alone.14 Encouraging safety and 
efficacy were observed in a multi -arm study 10mg/ kg nivolumab with three doublet cisplatin/ 
gemcitabine, cisplatin/pemetrexed or carboplatin/paclitaxel or nivolumab 5mg/kg combined with 
one doublet, carboplatin/paclitaxel in first line advanced NSLCC. Though the number of patients in each arm was small, special promise observed in the nivolumab 5mg/kg plus carboplatin 
paclitaxel arm with 2 year survivals of 62%.
[ADDRESS_700056] chemotherapy combined with PD -1 inhibitors.   
Given the single agent efficacy of ni volumab in SCCHN and the promising data with platinum -
based doublets and immune checkpoint inhibitors in NSCLC we propose to study weekly 
carboplatin and paclitaxel plus nivolumab as an induction regimen in resectable SCCHN. It is 
tenable that the addition of nivolumab to carboplatin and paclitaxel will be both well tolerated 
and improve efficacy including response, pathological complete response and long term disease control. The induction setting is especially appealing to study nivolumab added to weekly 
carboplatin paclitaxel in resectable SCCHN given the chance to rapi[INVESTIGATOR_537486], and the capacity to both determine the established predictive outcome of pathological complete 
response. Moreover, it affords the opportunity to obtain repeat tissue sampling for 
pharmacodynamics endpoint evaluation.    
Hypothesis:  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700057] immune response t hrough a number of 
mechanisms, including down regulation of tumor -specific antigen expression and presentation, 
secretion of anti -inflammatory cytokines, and upregulation of inhibitory ligands. In SCCHN, 
down- regulation of T- cell function is thought to be mediated by [CONTACT_16000]: i.) 
Reduced expression of co- stimulating molecules of the B7 -CD28 family71; ii.) Increased 
expression of PD -L1 in tumor cells and tumor associated fibroblasts; and, iii.) Loss of HLA -class 
I and selective down- regulation of  HLA-A,B,C locus expression resulting in defective antigen 
presentation16,17,18. In a subset of HPV -infected SCCHN, data shows that antigen -processing 
machinery components are downregulated compared to the adjacent normal squamous epi[INVESTIGATOR_537487] e activation of tumor specific T cells or suboptimal target recognition 
enabling tumor progression19. T cell checkpoint regulators such as CTLA -4 and programmed 
death- 1 (PD -1, CD279) are cell surface molecules that, when engaged by [CONTACT_20378], 
induce signaling cascades down- regulating T cell activation and proliferation.PD -1 engagement 
on T-cells by [CONTACT_4002]- L1-positive APC or PD -L1-positive tumor cells in the tumor microenvironment 
may limit effective immune responses. Conversely, PD -L1 expression may  be a positive 
prognostic factor as it may indicate infiltration of tumor -specific T cells that secrete IFN -γ, which 
upregulates PD -L1 expression. Consistent with this hypothesis is the co- localization of lymphoid 
cell infiltrates and PD -L1 staining observ ed in human melanoma lesions26. PD -L1 expression in 
SCCHN has been reported, preliminary results from a phase 1 trial in patients with 27 recurrent or metastatic disease observed that 77.9% of patients tested (N=104) expressed PD -L1, 
defined as ≥ 1% of stained cells in the tumor microenvironment.  
The role of the PD -[ADDRESS_700058] of care docetaxel.
16 In squamous cell carcinoma of the head and neck, CheckMate 
CA209141 study, is a randomized, open- label, phase 3 trial that compared nivolumab, a fully 
human anti -progr ammed death 1 (PD -1) monoclonal antibody, to investigator’s choice (IC) of 
systemic therapy in patients with recurrent or metastatic SCCHN who progressed from a platinum containing therapy.
17 At a preplanned interim analysis, the median OS was 7.5 months 
(95% confidence interval [CI], 5.5 to 9.1) with nivolumab versus 5.1 months (95% CI, 4.0 to 6.0) 
with IC. There is a 30% reduction in the risk of death for patients on the nivolumab arm (hazard 
ratio 0.70; 97.73% CI, 0.51 to 0.96; P=0.0101) over standard of  care. The overall response rate 
(ORR) was 12.1% with nivolumab versus 7.4% with IC. In addition, the overall safety profile of 
nivolumab was favorable compared to standard of care. Clinical benefit seen in this 
chemotherapy pre -treated SCCHN suggests the potential clinical activity of nivolumab in earlier 
treatment setting.  
Combination of Nivolumab and chemotherapy 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700059] been shown to 
inhibit the cytolytic activity of tumor infiltrating T -cells (e.g., PD -L1 expression; TGF -beta). In 
addition, some tumor -derived factors are able to enhance immune system counter -regulatory 
systems (e.g., increased T -regulatory cells). Finally, suboptimal tumor antigen delivery and 
presentation has been postulated as another mechanism by [CONTACT_537504].  
Cancer therapeutics such as chemotherapy may modulate tumor/immune- system interactions in 
favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to antigen- presenting cells. Tumo r cell death may also lead to 
a reduction in soluble and membrane -bound factors inhibiting tumor -infiltrating T -cells. 
Chemotherapy may also disrupt immune system regulatory networks by [CONTACT_104115] 
T-regulatory cells.  
Clinical insights into the t oxicity and efficacy of combination nivolumab chemotherapy can be 
gleaned from a trial in NSCLC.  Nivolumab added to chemotherapy has been evaluated in several cohorts of chemotherapy -naive subjects with advanced NSCLC in study CA209012.
18 
Nivolumab 10 mg/ kg was combined with gemcitabine + cisplatin (12 patients), pemetrexed + 
cisplatin (15 patients) and Nivolumab 10 mg/kg, and 5 mg/kg, was combined with paclitaxel and 
carboplatin (15 and 14 patients respectively).  
The safety profile of nivolumab plus plati num-doublet chemotherapy reflects additive toxicities of 
the individual agents, which were manageable using established safety guidelines (Table 1.1.5-1). The frequency of most immune- related select AEs was higher than what has been observed 
for nivolumab monotherapy. However, these treatment -related AEs, including pneumonitis, were 
effectively managed and did not lead to any deaths.  
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 29 of 124  
  
 
Activity was also evaluated by [CONTACT_4002] -L1 expression and was observed in subjects with both PD -L1 
expressing and non- expressing tumors (Table 1.1.4- 3). Overall, 79% (44/56) of subjects had 
evaluable tumor samples. At the 1% expression level, the response rate was 48% and 43% for 
expressers and non- expressers, respectively. The 1- year overall survival was 70% and 76% for 
expresser s and non- expressers, respectively.  
 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 30 of 124  
  
 
 
Given the small number of patients in the study, conclusions are tentative. However, the data 
are consistent with the conclusion that the predictive value for PD -L1 expression may be 
attenuated in the nivolumab + chemotherapy setting, compared to what has been observed in the nivolumab monotherapy and nivolumab + ipi[INVESTIGATOR_537488]. In NSCLC, there was no detectable diminution in activity for patients with PD -L1 non -expressing tumors, and 
response rates appear to be greater than in patients with P D-L1 non -expressing tumors treated 
with nivolumab, or nivolumab + ipi[INVESTIGATOR_125]. In patients with PD -L1 expressing tumors, 
nivolumab + chemotherapy showed a similar response rate compared to the N3 nivolumab + ipi[INVESTIGATOR_537489], but with higher toxicity. In patients with PD -L1 non- expressing tumors, 
nivolumab + chemotherapy showed a higher response rate compared to any of the nivolumab + 
ipi[INVESTIGATOR_537489].   
1.3 Correlative Studies  
PDL1 expression  
Immune inhibitory receptors are expressed by [CONTACT_20405], tumor -infiltrating macrophages, and 
peripheral blood monocytes. Nivolumab has the capacity to alter expression of PDL1 in these cells. Therefore, we plan to monitor changes in PDL1 expression in these different cell subsets 
by [CONTACT_537505]. 
 
Analysis of peripheral blood mononuclear cells and cytokines 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700060] been no studies looking at the capacity of nivolumab 
to alter immune bias or macrophage polarization. Therefore, we plan to analyze peripheral blood mononuclear cells (PBMC) subsets before treatment to establish a baseline and at every 
blood draw thereafter to monitor changes in these compartments due to nivolumab therapy.  We 
will stain PBMC with monoclonal antibodies specific for human CD3, CD4, CD8, CD11b, CD11c, CD14, CD33, CD163, CD204, and HLA -DR. Samples will be analyzed by [CONTACT_8315]. These phenotypic markers will enable us to monitor the effect of nivolumab therapy sizes of cell populations and activation status.  
We routinely perform multiplex cytokine analyses on serum samples in our astrocytoma clinical trial. We p lan to utilize magnetic Milliplex assays (HCYTOMAG -60K) to track changes in serum 
cytokines over the course of treatment.  
Exosomes and nivolumab therapy  
Exosomes are small membranous vesicles released by [CONTACT_537506]. In order to accomplish these tasks, 
exosomes contain a variety of RNA species including miRNA, protein and specialized lipi[INVESTIGATOR_805]. 
These attributes make exosomes attractive therapeutic targets, excellent biomarkers, and 
indicators of therapeutic responses. We have developed novel flow cytometric analyses where 
we utilize fluorescent dyes to track and quantify exosomes directly from patient sera. We plan to 
monitor exosomes levels in patient sera and look for changes in fre quency or content following  
nivolumab therapy.  
Patient Reported Outcomes (PRO):  
There has been increasing recognition that Patient -Reported Outcome (PRO) measures —
including, in particular, measures of health- related quality of life (HRQOL) —can convey 
essential supplementary information for assessing the overall burden of cancer and the 
effectiveness of interventions [ 21]. Hence, we will collect Functional Assessment of Cancer 
Therapy - General (FACT -G) and cancer specific FACT scales. The FACT questionnaires have 
been used by [CONTACT_537507] [22] .It has also been s hown that depression is the most frequently found psychological 
symptom among individuals with cancer, up to 38% of cancer patients meeting criteria for a diagnosis of major depression [ 23]. Prevalence rates of depression in cancer patients differ 
extensively across studies [ 24, 25]. Previous studies have also shown that depression might 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700061] behavior and adherence to medical treatment [ 26].Hence, we will collect Patient Health 
Questionnaire  (PHQ2&9).  The PHQ -[ADDRESS_700062] two items of the PHQ -9.  It is a screen 
for depression; patients who screen positive are further evaluated with the PHQ -9 which is used 
for making a criteria -based diagnosis of depression (based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM )-IV criteria for depression).  The PHQ -2 has been v alidated in 
several studies [27].  The diagnostic validity of the PHQ was established in two large studies in 
primary care and obstetrics [28].   
 
Additional Lab tests and waist to hip ratio:  
C - reactive protein (CRP) is an acute phase reactant [ 29], which reflects tissue injury .It is also 
a well -established marker for inflammation[3 0]. However, in recent literature it has also been 
shown to be a predictive biomarker for immunotherapy [31], elevated CRP also predicted 
prognosis and treatment response[ 32]. The frequency of significant Immune Related adverse 
Events (irAE) in Immune Checkpoint Inhibitors (ICI) treat ed patients are about 10– 20% and 
early recognition is critical to prevent serious morbidity and even mortality [33]. New onset 
autoimmune Diabetes Mellitus (DM) associated with immune checkpoint inhibitor treatment is 
extremely rare  [33, 3 4]. Even though it is very rare possibility having Glycated Hemoglobin 
(HbA1c) levels will be beneficial to capture these rare events. Lipid metabolism is altered in proliferating cells and impact tumor progression[3 5, 36].  Therefore, tumor dependence towards 
lipi[INVESTIGATOR_537490].  
 Waist to hip ratio (WHR) has been associated with metabolic syndrome and higher mortality [37, 
38]. Hence, WHR should be assessed in combination with BMI as part of risk  assessment for 
obesity related premature mortality and risk of metabolic related conditions.  
 
1.[ADDRESS_700063] common types of immune -mediated adverse events include endocrinopathies, diarrhea/colitis, hepatitis, 
pneumonitis, nephritis and rash. In the combination regimen, the frequency and intensity of 
these events may vary and depend on the specific dose and schedule used.  
• The safety of this drug combination with chemotherapy in Non- small cell lung cancer has 
shown the following. 
18 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 33 of 124  
  
The safety of chemotherapy vs. chemotherapy plus pembrolizumab in NSCLC assists in making 
a judgement about the combination of nivolumab plus chemotherapy, and thus, the randomized 
chemotherapy plus/minus pembrolizumab data are instructive.19 The incidence of grade 3 or 
worse toxicities were 39% and 26% with chemotherapy plus pembrolizumab vs. chemotherapy alone. There was 1 and 2 treatment related deaths in the pembrolizumab containing vs. control arm respectively. The authors concluded the triplet pembrolizumab containing regimen was 
tolerable.  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 34 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 35 of 124  
 1.4.2  Benefits  
Clinical activity of nivolumab monotherapy in patients with recurrent or metastatic SCCHN who 
progressed from a platinum containing therapy evaluated in CA209141 randomized phase 3 
study, demonstrated prolonged survival benefit with nivolumab as compared to investigator’s choice (IC) of chemotherapy. In this population, the safety profile of ni volumab was shown to be 
favorable as compared to standard of care chemotherapy. The addition of pembrolizumab to platinum doublets in NSCLC improved response and progression free survival compared to 
chemotherapy alone and of nivolimab plus platinum doublets compared to historical controls.  
Given the activity of both platinum doublets and nivolumab in head and neck cancer, these NSCLC data support the promise of improved pathologic response at the primary site of 
combination platinum doublet plus nivolumab in head and cancer.   
2 Study Objectives  
2.1 Objectives  
2.1.1  Primary  
The primary objective of the study is to estimate pathologic complete response (pCR) at the primary site in patients with newly diagnosed and untreated Stage III -IVA SCCHN of the oral 
cavity, Oropharynx, Larynx, and Hyopharynz with Nivolumab, paclitaxel and carboplatin in addition to standard chemotherapy.  
2.1.2  Secondary  
• Safety  
• Complete Pathologic Response at all sites of disease 
• Major pathologic response rate at primary site  
• Overall Clinical Response Rate  
• Clinical Complete Response Rate  
• 1 year PFS.  
• Overall survival.  
2.1.3  Exploratory  
• To explore whether PDL1 expression is associated with treatment response 
• To explore whether there is a net change in the Th1/Th2 ratio (IFN -γ, IL-4, IL10, etc.) or 
cell subset frequencies (M2 monocytes, myeloid- derived suppressor cells, etc.) within a 
patient’s peripheral blood either at baseline or in response to treatment is associated 
with treatment response  
• To explore whether exosomes or other immune related serum biomarkers change after combination therapy.  
• To explore the predictive value of serial cell free DNA levels and response  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 36 of 124  
 The aims for collecting PROs are to identify risks for poor physical and mental health outcomes; 
examine bio- behavior al factors associated with cancer treatment outcomes; and evaluate the 
physical and psychosocial needs of cancer survivors.   
 
Patient Reported Outcomes Measures -: Depression: PHQ2, PHQ9; Quality of Life: FACT- G 
and FACT- HN 
 
2.2 Endpoints/Outcome Measures  
2.2.1  Primary  
The primary objective of the study is to estimate the rate of pathologic complete response (pCR) 
at the primary site, defined as the absence of any residual invasive cancer on H&E evaluation of 
the resected specimen and all sampled ipsilateral lymph nodes, in patients with newly 
diagnosed and untreated Stage III -IVA SCCHN of the oral cavity, Oropharynx, Larynx, and 
Hypopharynx treated with standard neoadjuvant chemotherapy plus Nivolumab, paclitaxel, and 
carboplatin.  
2.2.2  Secondary  
Major pathologic response.  This is defined as 10% or less residual viable tumor (Hellmann M, 
Lancet Oncol. 2014).   
Safety will be continually assessed using the CTCAE version 5.0.  
Overall Survival (OS) is defined as the time between the date of study entry and the date of 
death. For subjects without documentation of death, OS will be censored on the last date the 
subject was known to be alive.  
The proportion of subjects with each category of overall clinical response will be summarized by 
[CONTACT_537508] (i .e., CR, PR, SD, PD, UE, ND). Beta(2,5) will be 
used as priors for combination regimens in calculating the posterior distribution of the pCR for 
each respective treatment group. Among subjects with measurable disease, a 95% credible 
region will be calculat ed for the odds ratio for each treatment combination relative to each other.  
The association of biomarkers with pCR will be completed univariably by t -test for continuous 
measures and by [CONTACT_60679] -square test for categorical marker measures (for example positive versus 
negative expression).  Longitudinal assessments of biomarkers will be assessed for association with pCR via linear mixed models of biomarker measures with pCR and treatment assignment and the interaction of pCR and treatment assignment as potential  covariates. Additional 
exploratory analysis of longitudinal biomarkers may be completed using latent class models, with pCR and treatment assignment as potential covariates to inform latent class membership.  
The specific hypotheses indicated will be completed via contrasts from the linear mixed models, 
as appropriate.  
2.2.3  Exploratory  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 37 of 124  
 Blood samples:  
There will be [ADDRESS_700064] will be >  1 < 4 weeks postsurgery.  (see study 
schedule 6.0). 
• PDL1 expression  
We plan to monitor changes in PDL1 expression on tumor cells, tumor -infiltrating 
macrophages, and circulating monocytes by [CONTACT_537509]. 
We will look for correlations between PDL1 expression on these cell subsets and 
treatment -induced clinical responses.  
 
• Immune bias  
We will monitor changes in immune bias during treatment using three assays.  
1) Changes in PBMC cell subset frequencies (M2 monocytes, myeloid- derived 
suppressor cells, etc.)  
2) Changes in patient serum cytokines (IL2, IL4 , IL10, IL13, IFNg, etc.)  
3) Changes in the capacity to polarization normal human monocytes in vitro.  
 
• Exosomes  
We will look for changes in exosome quantity and content following nivolumab and carboplatin plus paclitaxel . 
 
Tumor specimen:  
PD-L1 will also be assessed using IHC on the baseline tumor tissue and the surgical specimen.  
For this, the SP263 rabbit monoclonal antibody of Ventana will be used.  Note for the baseline, an archived formalin fixed paraffin embedded sample can be used.  Also, we anticipate that some patients will have a pCR. However, peri -cancerous tissue can also be PD -L1 assessed.   
Baseline p16 status will also be obtained for all oropharyngeal cancer patients.   
3 Study Design  
3.1 Characteristics  
This is a phase II trial looking at the combination of weekly carboplatin plus paclitaxel to which 
nivolumab is added as induction therapy prior to planned surgery for the definitive management 
of locally advanced squamous cell carcinomas of the head and neck.  
TREATMENT PLAN  
Induction Nivolumab + carboplatin + paclitaxel  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 38 of 124  
 • Nivolumab 240mg every 2 weeks x 3 doses (last dose at least 3 weeks before surgery)  
• Carboplatin AUC 2 weekly x 6 doses (last dose at least 2 weeks before surgery)  
• Paclitaxel 100 mg/m2 x 6 doses (last dose at least 2 weeks before surgery)  
 
Evaluation of Response to Chemotherapy  
Clinical response to chemotherapy will be measured by [CONTACT_537510].  PET/CT or , if patients cannot 
have a PET/CT, a CT or MRI will be obtained during the initial staging work -up for all patients. If 
the treating medical oncologist determines that there is evidence that the patient is progressing while on treatment (i.e., tumor size if found to be increased during treatment), imaging with MRI, 
CT, or ultrasound will be obtained for evaluation. For patients who are determined to have 
progression during treatment by [CONTACT_156650], study treatment will be discontinued 
and the patient will be considered for immediate surgery, as determined by [CONTACT_537511]. Finally, pathologic response will be assessed in the final tumor specimen, and attainment of pathologic complete response at primary  site (defined as the 
absence of any residual invasive cancer on H&E evaluation of the resected primary cancer specimen) will be determined by [CONTACT_537512]. Pathologic complete response of the entire 
tumor will also include all sampled lymph nodes.  
Surgery  
All patients will undergo surgery after completing the induction regimen.  Surgery will be scheduled at least [ADDRESS_700065] dose of carboplatin and paclitaxel.   
3.2 Number of Participants  
37 participants . Enrollment will be competitive across al l the sites.  
3.3 Duration of Therapy 
6 weeks  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700066] meet all of the following inclusion criteria in order to be eligible to participate in the study:  
1. Patients must be [ADDRESS_700067] s tage III -IV disease without distant metastases (M0) of 1) oral cavity, 
2) larynx, 3) hypopharynx  4) oropharynx (HPV neg) using AJCC [ADDRESS_700068] oropharyngeal cancer that is HPV positive , Stage II-III disease 
without distant metastases (M0)  using AJCC 8th edition  
5. All patients with  oropharyngeal SCCHN must be tested for HPV (by p16 and/or HPV ISH 
or PCR)  
6. Patients must be evaluated by a head and neck surgeon and be deemed surgically 
resectable at baseline.  
7. Tumor sample must be available for HPV p16 and  PD-L1 testing and if oropharyngeal, 
must be tested for HPV p16 
8. ECOG Performance status 0- 1. 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 40 of 124  
 9. Adequate organ function:  
o While blood cells 2000/ul or more  
o Absolute neutrophil count 1500/ul or more;  
o Platelets 100,000/ul or more,  
o Hemoglobin 9 g/dl or more; (transfusion permitted)  
o Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with 
Gilbert syndrome, who can have total bilirubin <3 mg/dl);  
o AST and  ALT less than or equal to 3 x the upper limit of normal,  
o GFR greater than or equal to 40 ml/min using the Cockcroft -Gault formula or 
Serum creatinine less than or equal to 1.[ADDRESS_700069] 
(minimum sensitivity 25 IU/L or equivalent units of HCG) within [ADDRESS_700070] dose of study drugs. “W omen of 
reproductive potential” is defined as any female who has experienced menarche and 
who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or 
who is not postmenopausal. Menopause is defined clinically as [ADDRESS_700071] a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.  
12. Men of reproductive potential who are sexually active with women of reproductive 
potential must use any contraceptive method with a failure rate of less than 1% per year.  
Men who are receiving the study medications will be instructed to adhere to 
contraception for [ADDRESS_700072] dose  of study drugs.  Men who are 
azoospermic do not require contraception.  
13. Informed Consent:  All subjects must be able to comprehend and sign a written informed consent document.  
4.1.2  Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Primary nasopharyngeal carcinoma.  
2. Patients who have participated in a study with an investigational agent or device within 2 weeks of initiation of treatment.  
3. Any prior radiotherapy to the neck.  
4. Any prior treat ment for SCCHN.  
5. Any prior therapy with anti -PD-1, anti -PD-L2, anti -CTLA -4 antibody, or any other 
antibody or drug specifically targeting T -cell co -stimulation or immune checkpoint 
pathways  
6. Any history of a sever hypersensitivity reaction to any monoclonal antibody.  
7. Any history of allergy to the study drug components.  
8. Any concurrent malignancies - exceptions include-  basal cell carcinoma of the skin, 
squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy.  Patients with a history of other prior 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700073] -diagnosis.  
9. Any diagnosis of immunodeficiency or current immunosuppressive therapy including >10mg/day of prednisone within 14 days of enrollment is not permitted  (excludes 
emergency transient steroid use at discretion of the treating physician).     
10. Patients that have an active autoimmune disease requiring systemic treatment within t he 
past 3 months or a documented history of clinically severe autoimmune disease, or a 
syndrome that requires systemic steroids (> 10 mg daily prednisone equivalents)  or 
immunosuppressive agents. Subjects with vitiligo, type I diabetes mellitus, or resolv ed 
childhood asthma/atopy would be an exception to this rule. Inhaled or topi[INVESTIGATOR_8826], 
and adrenal replacement steroid doses ≤10 mg daily prednisone equivalent, are 
permitted in the absence of active autoimmune disease.  Subjects with hypothyroidism 
stable on hormone replacement or Sjorgen’s syndrome will not be excluded from the 
study .  
11. Patients with a known Human Immunodeficiency Virus infection (HIV 1/2 antibodies) or 
Acquired Immunodeficiency Syndrome (HIV/AIDS), active Hepatitis B (e.g., HBsAg 
react ive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).  
12. Patients with evidence of non- infectious pneumonitis or history of interstitial lung 
disease.  
13. Patients who have received a live vaccine within [ADDRESS_700074] not be receiving any other investigational agents.  
15. Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse 
disorder(s) that would interfere with cooperation with the requirements of the trial.  
16. Women must not be pregnant (as above) or breastfeeding.  
4.2 Gender/Minority/Pediatric Inclusion for Research   
We will not exclude potential subjects from participating in this study based on ethni c origin or 
socioeconomic status. Every attempt will be made to enter all eligible patients in this protocol and therefore address the study objectives in a patient population representative of the entire 
head and neck squamous cell cancer population treat ed at Thomas Jefferson University 
Hospi[INVESTIGATOR_307]. There is nearly a 3:1 predominance of males to females in this diagnosis. We will review accruals to this trial quarterly in the Head and Neck MDG and review the number of 
males and females accrued. If this deviates from the expected ratio we will review our actual patient ratio for that time and determine a remediation plan within the MDG to ensure accrual of 
women.  
4.3 Strategies for Recruitment and Retention 
37 subjects will be recruited. Potential research subjects will be identified by a member of the patient’s treatment team, the protocol investigator, or research team at participating centers 
from Medical Oncology, Radiation Oncology and Surgical offices.  Investigators will screen the 
patient’s medical records for suitable research study subjects and discuss the study and their potential for enrolling in the research study. Patients will be screened based on pathology, 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 42 of 124  
 image studies etc. 37 patients will be enrolled (see Statistical Analysis Plan) with replacement of 
patients who do not begin therapy.  
4.4 Sub-Site Enrollment Procedure  
When a potential patient is identified at the sub -site, the Thomas Jefferson University (TJU)  
study site contact[CONTACT_537513] [ADDRESS_700075] : 
1. Notify them of the pending patient registrat ion 
2. Email registration documents  
3. Communicate the desired timeline of the registration.  
The sub- site must include the eligibility checklist, signed informed consent, and any applicable 
documentation supporting eligibility.  
Once eligibility has been confir med locally , TJU study site contact [CONTACT_537514]-site site to confirm eligibility . The participant will then 
be assigned a registration number. This number is unique to the participant on this trial and 
must be used moving forward.  The TJU Research Nurse/Coordinator will enter patients enrolled 
at the sub -site into the protocol management system, JeffTrial.  
A master study enrollment log will be maintained by [CONTACT_326546]. The sub -site site will also be asked to maintain an enrollment/screening log on -site, 
and email  this information to the TJU Study Site Contact  [CONTACT_326547] a month.   
Patients cannot be registered to this study on the weekends. If a patient is to be registered on a Friday, the sub-site will need to contact [CONTACT_537515].   
If a patient is enrolled at the sub-site without approval from the lead site, TJU will:  
1)  Temporarily suspend the sub-site  
2)  Complete mandatory re- training of staff at the sub-site on the enrollment process.  
This training will be fully documented.  
If enrollment without approval occurs a second time, the sub-  site will not be able to continue to 
participate in this study.  
4.5 Participant Withdrawal  
4.5.1  Reasons for Withdrawal  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700076].  
An investigator may terminate a study participant ’s participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best interest of the participant . 
• The participant  meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation.  
4.5.2  Handling of Participant  Withdrawals and Participant  Discontinuation of 
Study Intervention  
Patients who are discontinued from the study prior to initiation of study drug will not be 
consider ed as evaluable for this study and will be replaced.  
4.6 Premature Termination or Suspension of Study  
This study may be suspended or prematurely terminated if there is sufficient reasonable cause.  
Written notification, documenting the reason for study suspension or termination, will be 
provided by [CONTACT_87077], funding agency, the Food and 
Drug Administration (FDA) and regulatory authorities.  If the study is pr ematurely terminated or 
suspended, the principal investigator [INVESTIGATOR_33894](s) 
for the termination or suspension.  
Circumstances that may warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participant s. 
• Insufficient adherence to protocol requirements.  
• Data that is  not sufficiently complete and/or evaluable.  
• Determination of futility.  
[ADDRESS_700077]  
• Nivolumab  
• Paciltaxel  
• Carboplat in 
5.[ADDRESS_700078] Description  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 44 of 124  
 Nivolumab:  
Nivolumab (also referred to as BMS -936558 or MDX1106) is a human monoclonal antibody 
(HuMAb; immunoglobulin G4 [IgG4] -S228P) that targets the programmed death- 1 (PD -1) cluster 
of differentiation 279 (CD279) cell surf ace membrane receptor. PD -1 is a negative regulatory 
molecule expressed by [CONTACT_93247] T and B lymphocytes.1 Binding of PD -1 to its ligands, 
programmed death– ligands 1 (PD -L1) and 2 (PD -L2), results in the down- regulation of 
lymphocyte activation. Inhibition of the interaction between PD -1 and its ligands promotes 
immune responses and antigen -specific T -cell responses to both foreign antigens as well as 
self-antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced 
using standard m ammalian cell cultivation and chromatographic purification technologies. The 
clinical study product is a sterile solution for parenteral administration. OPDIVO  (nivolumab) is 
approved for use in multiple countries including the [LOCATION_002] (US, Dec -2014), the 
European Union (EU, Jun- 2015), and Japan (Jul -2014).  
Carboplatin  
Carboplatin, like cisplatin, produces predominantly interstrand DNA cross -links rather than DNA -
protein cross -links. This effect is apparently cell -cycle nonspecific. The aquation of c arboplatin, 
which is thought to produce the active species, occurs at a slower rate than in the case of 
cisplatin. Despi[INVESTIGATOR_60193], it appears that both carboplatin and cisplatin induce equal 
numbers of drug- DNA cross -links, causing equivalent lesi ons and biological effects. The 
differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates.  
In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact 
carbopl atin decay in a biphasic manner after a 30 -minute intravenous infusion of 300 to 500 
mg/m2 of carboplatin. The initial plasma half -life (alpha) was found to be 1.1 to 2 hours (n=6), 
and the postdistribution plasma half -life (beta) was found to be 2.6 to 5. 9 hours (n=6). The total 
body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The Cmax values and areas under the plasma concentration vs time curves from 0 to infinity (A UC inf) increase linearly with dose, although the 
increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 -  500 mg/m2).  
Carboplatin is not bound to plasma proteins. No significant quantities of proteinfree, 
ultrafilterable platinum -containing species other than carboplatin are present in plasma. 
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is 
slowly eliminated with a minimum half -life of 5 days.  
The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 
hours and 71% of the dose within 24 hours. All of the platinum in the 24 -hour urine is present as 
carboplatin. Only 3 to 5% of the administered platinum is excreted in the urine between 24 and 
96 hours. There are insufficient data to determine whether biliary excretion occurs.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 45 of 124  
 In patients with creatinine clearances below 60 mL/min the total body and renal clearances of 
carboplatin decrease as the creatinine clearance decreases. PARAPLATIN Bristol -Myers 
Squibb Company Approved 1.[ADDRESS_700079] with antitumor activity. TAXOL (paclitaxel) is obtained via a semi -
synthetic process from Taxus baccata. The chemical name [CONTACT_537534] 5β,20 -Epoxy -
1,2α,4,7β,10β,13α -hexahydroxytax -11-en-9-one 4,10- diacetate 2- benzoate 13- ester with 
(2R,3S) -N-benzoyl -3-phenylisoserine. Paclitaxel has the following structural formula: Paclitaxel 
is a white to off -white crystalline powder with the empi[INVESTIGATOR_62497] C47H51NO14 and a 
molecular weight of 853.9. It is hig hly lipophilic, insoluble in water, and melts at around 216–
217° C. CLINICAL PHARMACOLOGY Paclitaxel is a novel antimicrotubule agent that promotes 
the assembly of microtubules from tubulin dimers and stabilizes microtubules by [CONTACT_374121].  This stability results in the inhibition of the normal dynamic reorganization of 
the microtubule network that is essential for vital interphase and mitotic cellular functions. In 
addition, paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell 
cycle and multiple asters of microtubules during mitosis.
 
5.2.[ADDRESS_700080] pharmacy.  Each site will acq uire this agent through their pharmacies.  
 
5.2.2  Formulation, Packaging, and Labeling  
Nivolumab:  
 
Nivolumab, also referred to as BMS -936558- 01 or BMS -936558, is a soluble protein consisting 
of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. The 
physical and chemical properties of nivolumab are:  
 
BMS Number  BMS -936558 -01 
Other Names  Nivolumab, BMS -936558, MDX1106, ONO -4538, anti -PD-1 
Molecular Weight  146,221 daltons (143,619.17 daltons, protein portion)  
Appearance  Clear to opalescent, colorless to pale yellow liquid, light (few) 
particulates may be present  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 46 of 124  
 Solution pH  5.5 to 6.5  
 
Nivolumab Injection, 100 mg/10 mL (10 mg/mL) is a clear to opalescent, colorless to pale yellow 
liquid, which may contain light (few) particulates. The drug product is a sterile, non- pyrogenic, 
single -use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium 
chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 
(Tween  80), pH 6.[ADDRESS_700081] presentations i s the vial fill 
volume.  
Carboplatin  
PARAPLATINÆ (carboplatin aqueous solution) INJECTION is supplied as a sterile, pyrogen-
free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination 
compound. The chemical name [CONTACT_537535], diammine [1,1-  cyclobutane-
dicarboxylato(2- )-0,0í]-,(SP-4-2).  Carboplatin is a crystalline powder with the molecular formula 
of C6H12N2O4Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 Bristol -Myers Squ ibb Company Approved 1.0 Item 2 proposed.pdf Page 001 2 
of 24 mg/mL, and the pH of a 1% solution is 5 -7. It is virtually insoluble in ethanol, acetone, and 
dimethylacetamide.  
Paclitaxel  
TAXOL (paclitaxel) Injection is a clear, colorless to slightly yellow viscous solution. It is 
supplied as a nonaqueous solution intended for dilution with a suitable parenteral fluid 
prior to intravenous infusion. TAXOL is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel, 527 mg of purified Cremophor® EL* (polyoxyethylated castor oil) and 49.7% (v/v) dehydrated alcohol, USP.  
 
5.2.[ADDRESS_700082] Storage and Stability  
Nivolumab:  
Vials of nivolumab injection must be stored at 2° C to 8 °C (36 °F to 46 °F) and protected from light 
and freezing.  
The administration of nivolumab infusion must be completed within 24 hours of preparation. If 
not used immediately, the infusion solution may be stored under refrigeration conditions (2°C to 
8°C, 36°F to 46°F) for up to 24 hours, and a maximum of 8  hours of the total 24 hours can be at 
room temperature (20 °C to 25° C, 68 °F to 77 °F) and room light. The maximum [ADDRESS_700083] administration peri od. 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 47 of 124  
 Carboplatin  
Unopened vials of PARAPLATIN (carboplatin aqueous solution) INJECTION are stable to the 
date indicated on the package when stored at 25° C (77° F); excursions permitted from 15° -30° 
C (59° -86° F) [see USP Controlled Room Temperature]. Protect from light. PARAPLATIN 
(carboplatin aqueous solution) INJECTION multidose vials maintain microbial, chemical, and physical stability for up to 14 days at 25° C following multiple needle entries. Parenteral drug 
products should be inspected visually for particulate matter and discoloration prior to 
administration. Solutions for infusion should be discarded 8 hours after preparation.
 
Paclitaxel  
Stability  
Unopened single- dose vials of TAXOL (paclitaxel) Injection for Dilution are stable until the date 
indicated on the package when stored i n the original package below 25 degrees  C. (Freezing 
does not adversely affect the product).  
5.3 Dosage, Preparation, and Administration  
Nivolumab:  
Nivolumab injection is to be administered as an IV infusion through a 0.2 -micron to 1.2 -micron 
pore size, low -protein binding (polyethersulfone membrane) in- line filter at the protocol specified 
doses and infusion times. It is not to be administered as an IV push or bolus injection. 
Nivolumab injection can be infused undilut ed (10 mg/mL) or diluted with 0.9% Sodium Chloride 
Injection, USP or 5% Dextrose Injection, USP to protein concentrations as low as 0.35 mg/mL. 
During drug product preparation and handling, vigorous mixing or shaking is to be avoided. 
Instructions for dilution and infusion of nivolumab injection may be provided in the clinical 
protocol, pharmacy binder, pharmacy manual, or pharmacy reference sheet. Care must be 
taken to assure sterility of the prepared solution as the product does not contain any 
antimicrobial preservative or bacteriostatic agent. Nivolumab infusions are compatible with polyvinyl chloride (PVC) or polyolefin containers and infusion sets, and glass bottles.  
Carboplatin  
Per standard of care  
Paclitaxel  
Per standard of care  
Dosage & Administrati on Time of Nivolumab  
The dose of nivolumab is a flat dose 240mg administered intravenously over at least 3 0 
minutes .  Do not co -administer other drugs through the same intravenous line. Flush the 
intravenous line at end of infusion.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 48 of 124  
 Frequency of Treatment : 
For the duration of the study, nivolumab is to be administered on a Q2 weeks and carboplatin 
and paclitaxel Q weekly.  On the weeks of nivolumab administration, it will precede 
chemotherapy administration.  
5.4 Dose Modifications and Dosing Delays  
Nivolumab:  
There will not be dose modifications  
• Renal Impairment:   The effect of renal impairment on the CL of nivolumab was evaluated 
in subjects with mild (GFR < 90 and ≥ 60 mL/min/1.73 m2; n=379), moderate (GFR < 60 
and ≥ 30 mL/min/1.73 m 2; n=179), or severe (GFR  <30 and ≥ 15 mL/min/1.73 m2; n=2) 
renal impairment compared to subjects with normal renal function (GFR ≥ 90 
mL/min/1.73 m2; n=342) in the PPK analysis. No clinically important differences in the 
CL of nivolumab were found between subjects with mild or moderate renal impairment 
and subjects with normal renal function. Data from subjects with severe renal impairment 
are too limited to draw conclusions on this population.  Thus, patients with severe renal 
impairment are excluded from the student presented here.  
 
• Hepatic Impairment:  The effect of hepatic impairment on the CL of nivolumab was 
evaluated in subjects with mild hepatic impairment (total bilirubin 1.[ADDRESS_700084] > ULN as defined using the National Cancer Institute criteria of hepatic dysfunction; 
n=92) compared to subjects with normal hepatic function (total bilirubin and AST ≤ ULN; 
n=804) in the population PK analyses. No clinically important differences in the CL of 
nivolumab were found between subjects with mild hepatic impairment and normal 
hepatic function. Nivolumab has not been studied in subjects with moderate (total bilirubin > 1.[ADDRESS_700085]) or severe hepatic impairment (total bilirubin 
> [ADDRESS_700086]).  
      
Dose Delays:  
Dose delay criteria apply f or all drug -related AEs.  
Tumor assessments for all subjects should continue as per protocol even if dosing is delayed.  
Nivolumab administration should be delayed for the following:  
• Any Grade ≥ 2 non -skin, drug -related adverse event, except for fatigue and  laboratory 
abnormalities  
• Any Grade ≥ 3 skin drug-related AE  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 49 of 124  
 • Any Grade ≥ [ADDRESS_700087], ALT, or total bilirubin that is within normal limits, 
delay dosing for drug -related Grade 2 toxicity  (Increase frequency of monitoring 
to every 3 days).  
o Any Grade ≥ 3 drug -related amylase or lipase abnormali ty that is not associated 
with symptoms or clinical manifestations of pancreatitis does not require dose 
delay. The TJU PI  [INVESTIGATOR_482493] ≥ 3 amylase or lipase 
abnormalities.  
• Any AE, laboratory abnormality or inter -current illness which, in the judgment of the 
investigator, warrants delaying the dose of study medication.  
Rescheduling:  
• Nivolumab may be delayed until the next planned carboplatin plus paclitaxel dose if the 
next carboplatin plus paclitaxel doses are scheduled within the nex t 12 days. This will 
permit periodic carboplatin plus paclitaxel dosing to be synchronized with nivolumab dosing.  
• It should be noted delay of nivolumab of a week could result in a dose of nivolumab on the last scheduled infusion of carboplatin plus paclit axel just 2 weeks before scheduled 
surgery which is permitted.  
Criteria to Resume Nivolumab Dosing:  
• Subjects may resume treatment with nivolumab when the drug- related AE(s) resolve(s) 
to Grade ≤ 1 or baseline, with the following exceptions:  
o Subjects may resume treatment in the presence of Grade [ADDRESS_700088] not experienced a Grade 3 drug- related  (non-radiation 
dermatitis) skin AE may resume treatment in the presence of Grade [ADDRESS_700089]/ALT AND total bilirubin values meeting discontinuation parameters should have treatment permanently discontinued.  
o Drug -related pulmonary toxicity, neurologic toxicity, and hepatic toxicity must 
have resolved to baseline before treatment is resumed. Subjects with persist ent 
Grade [ADDRESS_700090] 1 month 
may be eligible for retreatment if discussed with and approved by [CONTACT_537516] . 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700091] tapered down to an equivalent 
dose of prednisone ≤10 mg/day.  
o Drug -related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment.  
o Subjects who delay study treatment due to any Gr ade ≥ 3 amylase or lipase 
abnormality that is not associated with symptoms or clinical manifestations of 
pancreatitis, and that is assessed by [CONTACT_537517], 
may resume nivolumab when the amylase or lipase abnormality has resolved to 
Grade < 3. The TJU PI  [INVESTIGATOR_482508].  
Criteria to Discontinue Nivolumab 
Treatment with nivolumab should be permanently discontinued for any of the following:  
• Any Grade 2 drug- related uveitis or eye pain or blurred vision that does not respond to 
topi[INVESTIGATOR_20308] 1 severity within the re -treatment period 
OR requires systemic treatment  
• Any Grade ≥ 2 drug -related pneumonitis or interstitial lung disease that does not resolve 
to dose delay and systemic steroids  
• Any Grade 3 drug- related bronchospasm, hypersensitivity reaction, or infusion reaction, 
regardless of duration 
• Any Grade 3 non- skin, drug- related adverse event lasting > 7 days, with the following 
exceptions for uveiti s, pneumonitis, bronchospasm, diarrhea, colitis, neurologic toxicity, 
hypersensitivity reactions, infusion reactions, endocrinopathies, and laboratory abnormalities:  
o Any Grade 3 drug- related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic  toxicity, hypersensitivity reaction, or infusion reaction of any duration 
requires discontinuation.  
o Any Grade 3 drug- related endocrinopathies adequately controlled with only 
physiologic hormone replacement do not require discontinuation 
o Any Grade 3 drug- related laboratory abnormalities do not require treatment 
discontinuation except:  
 Grade 3 drug -related thrombocytopenia > 7 days or associated with 
bleeding requires discontinuation.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700092] (LFT) abnormality that meets the foll owing 
criteria require discontinuation (also see Hepatic Adverse Event Management 
Algorithm):  
 AST or ALT > 8x ULN  
 Total bilirubin > [ADDRESS_700093] or ALT > [ADDRESS_700094] and total bilirubin > [ADDRESS_700095]  
• Any Grade 4 drug -related  adverse event or laboratory abnormality, except for the 
following events, which do not require discontinuation:  
o Grade 4 neutropenia ≤ 7 days  
o Grade 4 lymphopenia or leukopenia  
o Isolated Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestati ons of pancreatitis and decrease to < Grade 4 
within 1 week of onset. The TJU PI  [INVESTIGATOR_368446] 4 amylase or 
lipase abnormalities  
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated 
with clinical sequelae and are corrected with supplementation/appropriate 
management within 72 hours of their onset  
o Grade 4 drug -related endocrinopathy adverse events such as adrenal 
insufficiency, ACTH deficiency, hyper - or hypothyroidism, or glucose intolerance, 
which resolve or are adequately controlled with physiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose controlling agents, 
respectively, may not require discontinuation after discussion with and approval 
from the TJU PI . 
• Dose delay of nivolumab which results in treatment interruption of > 2 weeks requires 
treatment discontinuation.  
• Dosin g delays lasting > 2 weeks from the previous dose that occur for non- drug-related 
reasons may be allowed if approved by [CONTACT_537516] .  
• Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a s ubstantial clinical risk to the subject with continued 
nivolumab dosing.  
Please see Appendix  D for Strategies to Treat Adverse Events.  
For subjects expected who require more than 4 weeks of corticosteroids or other immunosuppressants to manage an adverse event, consider the following recommendations  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 52 of 124  
 • Antimicrobial/antifungal prophylaxis per institutional guidelines to prevent opportunisti c 
infections such as Pneumocystis jiroveci and fungal infections.  
• Early consultation with an infectious disease specialist should be considered. Depending 
on the presentation, consultation with a pulmonologist for bronchoscopy or a gastroenterologist for endoscopy may also be appropriate.  
• In patients who develop recurrent adverse events in the setting of ongoing or prior immunosuppressant use, an opportunistic infection should be considered in the 
differential diagnosis.  
Treatment of Nivolumab Related Infusion Reactions  
Since nivolumab contain only human immunoglobulin protein sequences, it is unlikely to be 
immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthralgias, hypo-  
or hypertension, bronchospasm, or other symptoms.  
All Grade 3 or 4 infusion reactions should be reported as an SAE if criteria are met. Infusion 
reactions should be graded according to NCI CTCAE 5.0 guidelines.  
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines as appropriate:  
For Grade 1 symptoms:  (Mild reaction; infusion interruption not indicated; intervention not 
indicated)  
Remain at bedside and  monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes before 
additional niv olumab administrations.  
For Grade 2 symptoms:  (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [e.g., antihistamines, non- steroidal anti -
inflammatory drugs, narcotics, corticosteroids, bronchodilat ors, IV fluids]; prophylactic 
medications indicated for 24 hours).  
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the infusion 
is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms  
resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% 
of the original infusion rate. Monitor subject closely. If symptoms recur then no further nivolumab 
will be administered at that visit. Administer diphenhydrami ne [ADDRESS_700096] be recorded on the electronic case report form (eCRF). The following prophylactic premedications 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 53 of 124  
 are recommended for future infus ions: diphenhydramine 50 mg (or equivalent) and/or 
paracetamol 325 to 1000 mg (acetaminophen) should be administered at least 30 minutes 
before additional nivolumab administrations. If necessary, corticosteroids (recommended dose: 
up to 25 mg of IV hydrocortisone or equivalent) may be used.  
For Grade 3 or Grade 4 symptoms:  (Severe reaction, Grade 3: prolonged [i.e., not rapi[INVESTIGATOR_20309]/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospi[INVESTIGATOR_14138] 
[e.g., renal impairment, pulmonary infiltrates]). Grade 4: (life threatening; pressor or ventilatory 
support indicated).  
Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline, and treat 
the subject as follows. Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 1:1,000 
solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly 
for IV administration, and/or diphenhydramine 50 mg IV  with methylprednisolone 100 mg IV (or 
equivalent), as needed. Subject should be monitored until the investigator is comfortable that the symptoms will not recur. Nivolumab will be permanently discontinued. Investigators should follow their institutional guidelines for the treatment of anaphylaxis. Remain at bedside and 
monitor subject until recovery from symptoms. In the case of late- occurring hypersensitivity 
symptoms (e.g., appearance of a localized or generalized pruritus within 1 week after treatment), symptomatic treatment may be given (e.g., oral antihistamine, or corticosteroids).  
Chemotherapy Dose Modifications:  
Doses of carboplatin and paclitaxel may require reduction for hematologic or non- hematologic 
toxicities (see sections below). Dose adjustments should be made according to the organ 
system showing the greatest toxicity as graded according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE). Treatment may be delayed for up to two weeks. If a 
patient does not fulfill re- treatment c riteria by [CONTACT_14713], the responsible chemotherapy agent(s) 
should be discontinued. Table 5.A.[ADDRESS_700097] dose reduction, the chemotherapy will be discontinued, nivol umab 
therapy should also conclude and the patient will advance to surgery.  
Dose level reductions for paclitaxel and carboplatin  
Dose Level  Paclitaxel  
(mg/m2) Carboplatin  
(target AUC)  
Starting Dose  [ADDRESS_700098] Reduction  75 1.5 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700099] 1500 cells/mm3 and the platelet count is at least 100,000  cells/mm3. The 
severity of neutropenia increases with dose. Table 5.A.5.a summarizes the guidelines for dose 
modifications based on hematologic toxicities. Mid -week use of filgrastim (suggest 5μg/kg SC 
days 3 and 4) wil l be included.   
Table 5.A.5.a.  Dose adjustments for paclitaxel and carboplatin for 
hematologic toxicity are based on weekly  CBC results:  
ANC   PLT Dose Modification  
500-1500/mm3 or 75-100 000/mm3 1 week delay  
 
<500/mm3 or <75 000/ mm3 1 week delay then reduce dose 
(see table 5.A.5)  
Note:  
• If blood counts have not recovered to ANC>1500/mm3 and 
PLT>100,000/mm3after a two week delay, then proceed to surgery.  
• If febrile neutropenia occurs, discontinue chemotherapy and proceed to 
surgery, after recovery.  
• Filgrastim 5mg/kg SC , at physician’s discretion,  may be administered on 
any 2 days inclusive days 2 -6 (preferr ed days 3 & 4)  of each treatment 
week to reduce marrow suppression.  
Peripheral Neuropathy  
If grade 2 peripheral neuropathy occurs, the paclitaxel dose should be decreased by [CONTACT_30560] (see Table 5.A.5).  If grade [ADDRESS_700100] developed severe hypersensitivity reactions should not 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 55 of 124  
 be rechallenged with paclitaxel. The attending physician will make the ultimate determination of 
the advisability of continuing paclitaxel or not.   
Hepatic Toxicity  
Paclitaxel is not known to cause hepatic toxicity; however, its elimination m ay be delayed in 
patients with severe hepatic dysfunction. Therefore, the dose of paclitaxel in patients with 
hepatic dysfunction should be modified according to Table 5.A.5.d.  
 
Table 5.A.5.d.  Paclitaxel dose reductions for hepatic toxicity  
NCI Liver function abnormalities  Paclitaxel dose modification  
Grade 0 -1 No change  
Grade 2  Dose reduction (see table 5.A.5)  
 
5.[ADDRESS_700101] 
Description and 
Dosage Form  Potency  Primary 
Packagi
ng 
(Volume)
/ Label 
Type  Appearance  Storage 
Conditions  
(per label) 
Nivolumab BMS-
936558- 01 
Solution for 
Injectiona 100 mg 
(10 
mg/mL)  10 mL 
vial Clear to 
opalescent 
colorless to pale 
yellow liquid. May 
contain particles  2 to 8°C. Protect 
form light and 
freezing  
Drug Destruction:  
Sponsor/Investigator drug destruction is allowed provided the following minimal standards are 
met: 
On-site disposal practices must not expose humans to risks from the drug.  
On-site disposal practices and procedures are in agreement with applic able laws and 
regulations, including any special requirements for controlled or hazardous substances.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700102] be 
documented.  
Accountability and disposal records are complete, up -to-date, and available for BMS to review 
throughout the clinical trial period as per the study agreement. A copy of the drug destruction 
certificate  should be maintained for provision to BMS at the end of the study.  
It is the Sponsor Investigator’s responsibility to arrange for disposal of all empty containers, 
provided that procedures for proper disposal have been established according to applicable 
federal, state, local, and institutional guidelines and procedures, and provided that appropriate 
records of disposal are kept.  
Paclitaxel  
Paclitaxel must be obtained from commercial sources and will be provided and stored according to institutional guidel ines. Paclitaxel 100 mg/m2 will be administered intravenously weekly on a 
14-day cycle. Paclitaxel will be administered prior to carboplatin on the same schedule.  
The following adverse events are expected with the administration of Paclitaxel. For complet e 
information, see Package Insert.  
Carboplatin  
Carboplatin must be obtained from commercial sources and will be provided and stored according to institutional guidelines. Carboplatin AUC=2 will be administered weekly of a 14- day 
cycle. Carboplatin will be administered after paclitaxel.  
The dose of carboplatin will be adjusted for renal dysfunction to achieve a calculated AUC as 
defined by [CONTACT_537518]. The calculated GFR for the carboplatin dose will be 
based on the calculated creatinine clearance using the Cockroff -Gaul t formula.  
Calvert Formula for carboplatin dose:  
AUC Dose = 2.0 X (GFR + 25)  
WHERE GFR (Cockroff -Gault):  
GFR = (140 –  Pt. Age in Yrs) (Weight in Kg) X 0.85 (females) or 1.0 (males)  
Serum Creatinine X 72  
The GFR dosing should not exceed 125 mL/min under any circumstance. If the calculated 
creatinine clearance is larger than 125 mL/min, a clearance of 125 mL/min should be used.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700103] Administration  
Patient records will be reviewed for compliance with chemotherapy  and nivolumab treatments 
with all deviations and delays noted.  
5.7 Concomitant Medications/Treatments  
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial. If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discon tinuation from trial therapy or 
vaccination may be required. The investigator should discuss any questions regarding this with 
the [CONTACT_537536] final decision on any supportive therapy or vaccination rests with 
the investigator and/or the subje ct's primary physician. However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
Investigator, and the subject  
All treatments that the investigator considers necessary for a subject’s welfa re may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_77981]. All concomitant medication and therapi[INVESTIGATOR_537491] 
(CRF) including all prescription, over -the-counter (OTC) , herbal supplements, and IV 
medications and fluids. If changes occur during the trial period, documentation of drug dosage, frequency, route, and date should also be included on the CRF.  
All concomitant medications received within [ADDRESS_700104] dose of trial treatment should be recorded. Concomitant medications administered to treat SAEs and ECIs should be recorded as defined.  
The following medications are prohibited during the study (unless utilized to treat a drug related adverse event):  
• Immunosuppressive agents.  
• Immunosuppressive doses of systemic corticosteroids, with the following exceptions:  
o Subjects are permitted the use of topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, and 
inhalational corticost eroids (with minimal systemic absorption).  
o Adrenal replacement steroid doses > 10 mg daily prednisone are permitted.  
o A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non -autoimmune conditions (e.g., 
delayed- type hypersensitivity reaction caused by a contact [CONTACT_20435]) is permitted.  
• Any concurrent anti -neoplastic therapy (i.e., chemotherapy, hormonal therapy, 
immunotherapy, extensive, non -palliative radiation therapy, or standard or inves tigational 
agents for treatment of cancer.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 58 of 124  
 • The use of amifostine is not permitted.  
• The use of hematopoietic growth factors can be considered at the discretion of the 
treating physician  
• All other medications are permitted except those that are contraindicated in the 
exclusion criteria (section 4.1.2).  
Subjects are permitted to use topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic 
corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of 
corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non -autoimmune 
conditions (e.g., delayed- type hypersensitivity reaction caused by [CONTACT_13132]) is permitted.  
Although monoclonal antibodies are not direct inhibitors/inducers of metabolizing enzymes, recent literature reports suggest that therapeutic proteins that are modulators of cytokines may 
indirectly affect expression of cytochrome (CYP) enzymes. The indirect drug- drug interaction 
potential of nivolumab was assessed using systemic cytokine modulation data for cytokines known to modulate CYP enzymes, at single and multiple doses of 0.3 to 10 mg/kg Q3W from 
CA209009. There were no meaningful changes in cytokines known to have indirect effects on CYP enzymes across all dose levels of nivolumab (0.3, 2 and 10 mg/kg) during the course of 
treatment. This lack of cytokine modulation suggests that nivolumab has no or low potential for 
modulating CYP enzymes , thereby [CONTACT_124439] a low risk of therapeutic protein- drug interaction. 
Nivolumab is an IgG4 monoclonal antibody, which is eliminated by [CONTACT_537519], namely by [CONTACT_105]- specific catabolism (mainly by [CONTACT_537520]). These enzymes are not known to be inhibited or induced by [CONTACT_8422], 
and therefore it is unlikely that other drugs will have an impact on the PK of nivolumab.  
All supportive measures consistent with optimal patient care will be given throughout the study.  This includes the use of antiemetic therapy at the discretion of the treating physician, as well as 
pi[INVESTIGATOR_537492]. Use of these agents will be recorded on the data forms.  
Aggressive oral and skin can is recommended, as are anal gesics.  
The prophylactic placement of a gastrostomy tube before treatment begins is at the discretion of the treating physician but it not encouraged. It is strongly recommended for patients with 
significant dysphagia and weight loss.  
Salvage surgery may be performed after chemoradiotherapy is there is local and / or regional progression of disease.   
5.8 Dietary Restrictions  
There are no dietary restrictions  
6 Study  Schedule   
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 59 of 124  
 6.1 Enrollment/Baseline (Visit 1, Day 0)  
• Obtain and document consent from potential partici pant on protocol  consent form.  
• Review medical/dental history to determine eligibility based on inclusion/exclusion 
criteria.  
• Review medications history to determine eligibility based on inclusion/exclusion criteria.  
• Verify baseline tumor tissue specimen av ailable. FFPE core/excisional specimen 
archived is highly encouraged preferably with at least 5 cores. Tissue for frozen and 
FFPE core or excisional biopsy will be obtained as feasible.  
o Tumor sample prior to therapy is mandatory to confirm the presence of squamous cell carcinoma, for HPV p16 testing in oropharyngeal carcinomas, and 
for PD -L1 testing for all patients. If a recent (obtained within 3 months of 
enrollment without interim therapy as dictated in the eligibility criteria) tumor 
sample is not avail able at screening, a fresh biopsy will be taken prior to 
enrollment.  
• Perform medical examinations needed to determine eligibility, including complete head 
and neck examination including laryngoscopy. S tandard of care oral and maxillofacial 
examinations. Dental examination will be done before surgery; ok to be done after initiating systemic therapy on study.   
• Verify inclusion/exclusion criteria.  
• Obtain demographic information, medical/dental history, medication history, alcohol, and tobacco use history.  
• Reco rd results of physical including ECOG Performance Status, Vital Signs, Complete 
Physical Exam  (including BMI and waist to hip ratio [WHR]) . 
• Schedule study visits for individuals who are eligible and available for the initial treatments of the trial - carboplatin, paclitaxel, nivolumab.  
 
The following procedures must be completed within 28 days of study enrollment unless 
otherwise indicated:  
• PET/CT or, i f a patient cannot have PET/CT, then a CT or MRI of the Head and/or  Neck,  
and Chest , abdomen and pelvis  with and without contrast  must be completed within [ADDRESS_700105] only.  
• EKG  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 60 of 124  
 • Collect blood for baseline correlative studies (Luminex panel and exosomes), pre -
treatment serum chemistries (Albumin, LDH, AST, ALT, ALK Phos, T.Bili, BUN, 
creatinine, Calcium, Mag, Phos, Na, Cl, Phos, Glucose, Amylase, Lipase, TSH, Free T4, 
Free T3 , cortisol ), PT/PTT, CBC  with differential, viral studies (HepB surface antigen and 
hepatitis C antibody or hepatitis C RNA)  within 14 days of initiation of study treatment.  
• Serum or urine pregnancy test for women of childbearing potential  must be done within 
21 days of study enrollment . 
The following procedures will only be performed for patients en rolled at Thomas Jefferson 
University:  
• Complete PROs:  
o FACT -G 
o FACT -HN 
o PHQ2  
o PHQ9  
• C-reactive protein (CRP), glycated hemoglobin (HbA1c), and lipid panel  
• Body Mass Index (BMI) and Waist Hip Ratio (WHR)  
 
6.2 Treatment Period  
Visit 2, Week 1, Day 1-  RUN- IN TREATMENT PHASE  
• Targeted and complete physical examination 
• Review entry labs, performed within [ADDRESS_700106] ration.  
• Review concomitant medications.  
• Administer the nivolumab (dose #1) and paclitaxel plus carboplatin (dose #1).  
• Ensure that surgery dates and treatment planning are scheduled  
• Record adverse events as reported by [CONTACT_3445] (PRO -CTCAE) or observed by  
[CONTACT_1697].  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700107] agreed to the collection and if determined 
feasible by [CONTACT_099]. The tissue collected will be sent for formalin fixed/paraffin embedded and a portion may also be frozen.  
Visit 3 , Week 3, ±  4 days - (there will be no visit week 2.  Vi sits are every other week 
during systemic therapy induction)  
• Record adverse events as reported by [CONTACT_3445]  (PRO -CTCAE)  or observed by 
[CONTACT_1697].  
• Targeted and complete physical examination.  
• CBC with differential , CMP, Mag, Phos , Amylase, Lipase, LDH, TSH, cortisol, Free T4, 
and Free T3 prior to administration of the study drug; to be drawn within [ADDRESS_700108] for women of childbearing potential within 
24 hours of study drug administration  
• Review concomitant m edications.  
• ECOG Performance Status  
• Record adverse events reported by [CONTACT_537521] (dose #2) and paclitaxel plus carboplatin (dose #3). Visit 4, Week 5 ± 4 
days  (there will be no visit week 4.  Visits are every other week during systemic therapy 
induction)  
• Record adverse events as reported by [CONTACT_3445] (PRO -CTCAE) or observed by 
[CONTACT_1697].  
• Targeted and complete physical examination.  
• CBC with differential , CM P, Mag, Phos , Amylase, Lipase, LDH  prior to administration of 
the study drug; to be drawn within [ADDRESS_700109] for women of childbearing potential within 24 
hours of study drug administration  
• Review concomitant medications.  
• ECOG Performance Status  
• Draw correlative laboratory studies  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 62 of 124  
 Administer the nivolumab (dose #3) and paclitaxel plus carboplatin (dose #5). Visit 5, Week 8 ±  
4 days (Surgery scheduled)  
• CT scan Preop (morning of surgery or day prior)  
• Record adverse events as reported by [CONTACT_3445] (PRO -CTCAE) or observed by 
[CONTACT_1697].  
• Targeted and complete physical examination.  
• Correlative labs  
• ECOG Performance Status  
• CBC with differential , platelet count, CMP, Mag, Phos , amyl ase, lipase, LDH,  PT/PTT, 
TSH, T4, T3, cortisol  prior to  surgery  
• EKG  
• Intraoperative specimens sent fresh on ice for correlative studies.  
The following procedures will only be performed for patients enrolled at Thomas Jefferson 
University:  
• Complete PROs:  
o FACT -G 
o FACT -HN 
o PHQ2  
o PHQ9  
o C-reactive protein (CRP), glycated hemoglobin (HbA1c), and lipid panel  
 
Study Procedures- Administration of Paclitaxel and Carboplatin and Nivolumab and 
Surgery  
Cycle 1 -3 (Medical Oncologist): Each cycle is 2 weeks long.  Full medical history, general 
physical exam, clinical tumor assessment and measurement by [CONTACT_461], comprehensive metabolic panel (CMP), CBC, magnesium, phosphate, height, weight. Intravenous 
administration of paclitaxel 100 mg/m
2 and carboplatin AUC=2. ON Days 1 and 8 of each cycle, 
and Nivolumab 240 mg administered Day 1 of each cycle.  On week 8, surgery.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 63 of 124  
 Surgery will be performed approximately 2 weeks (Week 8) after the last dose of study 
treatment. Surgery is to be performed no later than [ADDRESS_700110] chemotherapy dose (to 
allow patients to recover after chemotherapy)  
 
6.[ADDRESS_700111]-Surgical /Follow -Up 
Visit 6, Week  9 ± 5 days    Postop visit  
• Postop evaluation and exam  
• Whole blood Collection – Correlative labs  
• Wound assessment  
• Safety Assessment  
The following procedures will only be performed for patients enrolled at Thomas Jefferson University:  
• Complete PROs:  
o FACT -G 
o FACT -HN 
o PHQ2  
o PHQ9  
• C-reactive protein (CRP), glycated hemoglobin (HbA1c), and lipid panel  
• Body Mass Index (BMI) and Waist Hip Ratio (WHR)  
Visit 7, 3 months ±[ADDRESS_700112] -surgical completion*  
• Focused physical assessment  
• History  
• Wound assessment  
• Whole Blood collection for correlative labs    
• PET scan at [ADDRESS_700113] treatment ±  2 week s.  
• Record adverse events as reported by [CONTACT_3445] (PRO -CTCAE) or observed by 
[CONTACT_537522] & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 64 of 124  
 *If post -op xrt, then repeat PET scan will be delayed to 3 months ± [ADDRESS_700114] chemo dose.  
6.4 End of Treatment Study Procedures  
Final Study Visit (Visit 8, 6 months ± [ADDRESS_700115] -surgical completion)  
Record adverse events as reported by [CONTACT_3445]  (PRO -CTCAE)  or observed by [CONTACT_1697].  
• Complete Physical Exam   
• Review concomitant medications.  
• Draw correlative laboratory studies (end of treatment time point).  
6.[ADDRESS_700116]-Treatment/Follow -Up 
Patient’s medical records will be reviewed every 3 months for the next 6 months to obtain 
information on survival and disease recurrence.  
Follow Up Imaging is to be completed per the institutional standards.  
6.6 Withdrawal Visit/Discontinuation of Therapy  
At the time of withdrawal from the study, patients will be offered the opportunity  to provide 
serum samples for correlative studies.  
Adverse events will be collected and recorded as will the reason for discontinuation.  
6.[ADDRESS_700117] 1.5 cm is mandatory. Surgical procedures can include transoral or transc ervical 
approaches with mandibulotomy or,  marginal, or segmental mandibulectomy as necessary. In 
all cases, an ipsilateral neck dissection will be performed. Bilateral neck dissection will be performed when contralateral lymph nodes are present, when the t umor extends to within 1 cm 
of midline, or at the surgeon’s discretion. Reconstruction will be performed as needed by [CONTACT_537523], regional, or free tissue flaps.  
6.8 Radiation  
After surgical resection, the decision for postoperative radiotherapy ±  concurrent chemotherapy 
will be determined by [CONTACT_537524]. Radiation therapy will start 4 to 6 weeks after 
surgery, if not postoperative complications occur.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700118] a thickness of 0.3 cm or smaller slices through the 
region that contains the primary target volumes.   
Volumes     
The prescribed radiotherapy dose will be 60- 66 Gy in 2 Gy once- daily fraction size (total of 30-
33 fractions), based on the status of the surgical margins and the presence of nodal extra 
capsular extension. Radiotherapy should begin on a Monday, Tuesday or Wednesday. 
Megavoltage energy photon beam irradiation is required.  
All plans must be normalized such of 95% of the volume of the PTVs are covered with the 
prescription dose. At 1 cc PTV volume, the dose should not be > 110% of the prescribed dose.  
Definition of Target Volumes CTV60: This volume will receive 2 Gy per day. CTV60 will include the pri mary tumor bed (based on preoperative imaging, preoperative physical exam/endoscopy, 
operative findings, pathologic findings) plus region(s) of grossly involved lymphadenopathy. CTV56: This will include all other regions felt to be at risk for harboring mi croscopic cancer that 
do not meet the criteria for CTV60. For example, this would apply to the contralateral hemineck 
being irradiated electively for base of tongue cancer. This volume will receive approximately 
1.85 Gy per day. CTV66: This would include a region or regions felt to be at especially high risk 
for recurrence (e.g., an area of positive margin of resection, or nodal extracapsular extension). This area will be receiving a daily fraction size of 2.0 Gy and will be delivered sequentially after 
the 60 Gy treatment will be finished.  
Image Guidance for Image Guided Radiation Therapy (IGRT)  
Daily image guidance of IMRT/VMAT will be achieved using linear -accelerator mounted kV or 
MV helical conebeam CT images. For those institutions that are using daily  IGRT the minimum 
CTV-to-PTV expansion is 3.0 mm.  
7 Study Procedures and Evaluations  
7.1 Study Procedures/Evaluations  
• Medical History including intercurrent illnesses and specific attention to autoimmune 
disorders, may be obtained from the medical record 
• Concomitant meds: prescription medications taken for the 28 days prior to enrollment  
• Physical exam: height, weight, obtained from the medical record  
• ECOG performance status from the medical record 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 66 of 124  
 • Obtain histologic confirmation of disease, including p16 st atus for oropharyngeal 
primaries from the medical record  
• Standard oral evaluation pre- radiation therapy by [CONTACT_537525]  
• Vital Signs  
The following procedures are only for patients enrolled at Thomas Jefferson University:  
• PROs are self -administered  
 
• Waist Hip Ratio:  measurement to be taken per the NHLBI, NIH guideline to 
measure waist circumference. 
https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf   
o To measure waist circumference,  locate the upper hip bone and the top of 
the right iliac crest. Place a measuring tape in a horizontal plane around 
the abdomen at the level of the iliac crest. Before reading the tape measure, ensure that the tape is snug, but does not compress the skin,  
and is parallel to the floor. The measurement is made at the end of a normal expi[INVESTIGATOR_1516].  
o Hip circumference should be measured around the widest portion of the buttocks, with the tape parallel to the floor.   
• Body Mass Index (BMI) to calculated as kg/m2  
 
7.2 Laboratory Procedures/Evaluations  
7.2.1  Clinical Laboratory Evaluations  
• Pregnancy Test: WOCBP prior to dosing nivolumab.  
• A serum or urine pregnancy testing is required within 24 hrs of starting study treatment  
• Laboratory testing prior to each dose of nivolumab: Within 72 hours prior to re -dosing-  
CBC w/ differential, LFTs, BUN or serum urea level, creatinine, Ca, Mg, Na, K, Cl, LDH, 
Glucose, amylase, lipase.  Within 72 hours prior to re -dosing-  TSH (with reflexive Free 
T4 and Free T3)  
7.2.2  Special Assays or  Procedures  
Please see accompanying laboratory manual  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 67 of 124  
 7.2.3  Specimen Preparation, Handling, and Storage  
Two 10 ml purple top tubes will be collected for correlative studies. Samples can be held at 
room temperature and will be brought directly to the Harshyne Laboratory: [ADDRESS_700119] 
Rm 606, Philadelphia, PA [ZIP_CODE], [LOCATION_003] . 
Samples collected at the sub- site will be sent to the Harshyne Laboratory. Please see the 
accompanying laboratory manual additional information.  
7.2.4  Specimen Shipment  
Please see accompanying laboratory manual  
8 Evaluation of Safety  
8.1 Specification of Safety Parameters  
8.1.1  Unanticipated Problems  
Unanticipated problems (UAPs) include,  in general, any incident, experience, or outcome that 
meets the following criteria:  
• unexpected in terms of nature, sever ity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved 
research protocol and informed consent document; and (b) the characteristics of the 
participant  population being studied;  
UAPs are considered to pose ri sk to participant s or others when they  suggest  that the research 
places participant s or others at a greater risk of harm (including physical, psychological, 
economic, or social harm) than was previously known or recognized.  
8.1.[ADDRESS_700120] or unfavorable medical occurrence in a human participant , 
including any abnormal sign (for example, abnormal physical exam or laboratory finding), 
symptom, or disease, temporally associated with the participant ’s participation in the research, 
whether or not considered related to the participant ’s participation in the research.  
8.1.3  Serious Adverse Events 
A serious adverse event (SAE) is one that meets one or more of the following criteria:  
• Results in death  
• Is life -threatening (places the participant  at immediate risk of death from the event as it 
occurred)  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 68 of 124  
 • Is disabling or incapacitating 
• Results in inpatient hospi[INVESTIGATOR_1081] 
• Results in a persistent or significant dis ability or incapacity  
• Results in a congenital anomaly or birth defect   
• An important medical event that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, the event may jeopardize the participant  or may require intervention to 
prevent one of the outcomes listed in this definition.  
• Suspected transmission of an infectious agent (e.g. pathogenic or nonpathogenic) via 
the study drug is an SAE  
• Although pregnancy, overdos e, cancer and potential DILI are not always serious by 
[CONTACT_8661], these events must be handled as SAEs  
Following the subject’s start of treatment , all SAEs, whether related or not related to study 
drug, must be collected, including those thought to be associated with protocol -specified 
procedures. All SAEs must be collected, that occur within 100 days of discontinuation of 
dosing.  
• A nonserious adverse event  is an AE not classified as serious.  
Non-serious Adverse Event Collection and Reporting:  
• The collection of nonserious AE information should begin at initiation of study drug. All 
treated related nonserious adverse events should be collected continuously during the 
treatment period and for a minimum of [ADDRESS_700121] dose of study 
treatment. During this time, the clinical research staff will call the patient monthly.  
8.2 Safety  Assessment and Follow -Up 
Adverse event reporting will begin after study treatment, unless AE/SAE is caused by a study 
specific screening procedure, and continue until 100 days  (for non -serious AEs) or 100 days (for 
SAEs) after the last day of study participation. At each study visit, the investigator (or designee) will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for 
outcom e information until resolution or stabilization.  
8.[ADDRESS_700122] be documented for each adverse event occurring during the time period specified in Section 8.2 Safety Assessment and Follow -Up.  
8.3.1  Relationship to Study Intervention  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700123] consider etiologies such as natural 
history of the underlying disease, concurrent illness, concomitant therapy,  study -related 
procedures, accidents, and other external factors.  
The following guidelines are used t o assess relationship of an event to study intervention:  
1. Related (Possible, Probable, Definite)  
a. The event is known to occur with the study intervention.  
b. There is a temporal relationship between the intervention and event onset.  
c. The event abates when the intervention is discontinued.  
d. The event reappears upon a re- challenge with the intervention.  
2. Not Related (Unlikely, Not Related)  
a. There is no temporal relat ionship between the intervention and event onset.  
b. An alternate etiology has been established.  
8.3.2  Expectedness  
The PI [INVESTIGATOR_326515]. An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the intervention. Risk information to assess 
expectedness can be obtained from preclinical studies, the i nvestigator’s brochure, published 
medical literature, the protocol, or the informed consent document.  
8.3.3  Severity of Event  
Adverse events will be graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.[ADDRESS_700124] be documented for all adverse 
events.  
8.4 Safety Reporting  
8.4.1  Reporting to IRB  
[IP_ADDRESS]  Unanticipated Problem s 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 70 of 124  
 Thomas Jefferson University: All incidents or events that meet criteria for unanticipated 
problems (UAPs) as defined in Section 8.1.1  Unanticipated Problems  require the creation and 
completion of an unanticipated problem report form  (OHR- 20).  
UAPs that pose risk  to participant s or others, and that are not AEs, will be submitted to the IRB 
on an OHR- 20 form via the eazUP system within 5  working days of the investigator becoming 
aware of the event.  
UAPs that do not  pose risk to participant s or others will be submitted to the IRB at the next 
continuing review.  
Sub-Site: All incidents or events that meet criteria for unanticipated problems (UAPs) as defined 
in Section 8.1.[ADDRESS_700125] also be reported to Thomas Jefferson University using the 
Unaticipated Problems Form (see Appendix F ). The TJU study site contact [CONTACT_537526]- site to the TJU IRB.  
[IP_ADDRESS]  Adverse Event s  
Grade 1 AEs  will be reported to the IRB  at continuing review .  
Grade 2 AEs will be reported to the IRB at the time of continuing review.  
[IP_ADDRESS]  Serious Adverse Event s  
Thomas Jefferson University:  
SAEs will be reported to the IRB on OHR -10 forms via the electronic reporting system (eSAEy) 
according to the required time frames described below.  
Grade 3- [ADDRESS_700126] possibly related to the study will 
be reported to the IRB within 2 working days of knowledge of the event.  
Grade 3- 4 AEs that are deemed unrelated to the study will be reported to the IRB within 5 
working days.  
Grade 5 AEs will be reported to the IRB within one working day of knowledge of the event.  
All SAEs will be submitted to the IRB at continuing review, including those that were reported 
previously.  
Sub-Sites:  
SAEs occurring at the sub- site are to be reported to the sub -site IRB per institutional guidelines. 
Section 8.4.2 provides information on reporting SAEs to TJU.   
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700127] via email or phone, followed by [CONTACT_537527] a formal report.   
SAEs should be reported to TJU using the Sub -Site Ser ious Adverse Event form (Appendix G) 
or the FDA Medwatch 3500A, and should comprise a full written summary, detailing relevant 
aspects of the adverse events in questions, including grading and attribution to study drug.  
Where applicable, information from relevant hospi[INVESTIGATOR_537493].   
SAE Reports should be signed by [CONTACT_17210] -site PI, and then emailed to the Thomas Jefferson 
University Study Site Contact [INVESTIGATOR_874] 24 hours.  
The TJU coordinator will notify the TJU PI [INVESTIGATOR_326516], and report these 
events to the TJU Medical Monitor/IRB appropriately (within 5 working days if it deems an 
amendment, or in a spreadsheet at the time of annual review if no amendment is necessary).  
Additional follow -up SAE re ports should be submitted when available.  
All reportable Adverse Events (AEs) should be reported to the TJU Research Coordinator within [ADDRESS_700128] be kept by [CONTACT_17210]- site on an ongoing tracking log to be reviewed 
by [CONTACT_326552] . 
Unanticipated problems (UAPs) that pose risk to subjects or others, and that are not AEs/SAEs should be reported to TJU within 5  working days using form Unanticipated Problems Form (see 
Appendix F) and should be email  to the Thomas Jefferson University study site contact [INVESTIGATOR_874] [ADDRESS_700129] for submission to the SKCC DSMC.  
For expedited reporting requirements, s ee table below:                                              
DSMC AE/SAE  Reporting Requirements  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 72 of 124  
   

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700130] be recorded on BMS or an approved form; pregnancies must be 
reported on a Pregnancy Survei llance Form.  
SAE Email Address:   [EMAIL_176]  
SAE Facsimile Number:   [PHONE_188]  
If only limited information is initially available, follow -up reports are required. (Note: Follow -up 
SAE reports should include the same investigator term(s) init ially reported.)  
If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes available, a follow -up SAE report should be sent within 24 hours to BMS (or designee) 
using the same procedure used for transmitting th e initial SAE report.  
All SAEs should be followed to resolution or stabilization.  
Site specific forms will be requested for review.  
The sponsor/investigator will be required to reconcile SAEs reported in  the clinical database 
with SAE cases transmitted t o BMS Global Pharmacovigilance (GPV&E); 
worldwide.safety@bms. BMS requests this to be done quarterly and prior to the database lock 
or final data summary.  
A summary of the process for the sponsor/investigator:  
• Sponsor/Investigator sends a request to BMS GPV&E for a “GPV&E reconciliation 
report”. Requests for reconciliation should be sent to [EMAIL_177]. The request should provide the BMS protocol ID, 
study title and PI, and sponsor/investigator protocol ID.  
• BMS will send a report back to t he sponsor/investigator. The data elements listed on 
the GPV&E reconciliation report will contain information the investigator can use for 
individual case identification. Cases on the list from BMS GPV&E should be compared to the SAE cases in the clinical database.  
• If the sponsor/investigator determines a SAE case was not transmitted to BMS GPV&E, the case should be sent immediately to BMS  
The sub- site will complete the Medwatch [ADDRESS_700131] be reported to the Food and Drug Administration (FDA) as soon as possible 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 74 of 124  
 and no later than 7 days (for a death or life- threatening event) or 15 days (for all other SAEs) 
after the investigator’s or institution’s initial receipt of the information. BMS will be provided with 
a simultaneous copy of all adverse events filed with the FDA.  
SAEs should be reported on MedWatch Form 3500A, which can be accessed at: 
http://www.accessdata.fda.gov/scripts/medwatch/.  
MedWatch SAE forms should be sent to the FDA at:  
MEDWATCH  
[ADDRESS_700132]  
Rockville, MD [ZIP_CODE]- 9787 
Fax: 1 -800-FDA-0178 (1- [PHONE_189])  
http://www.accessdata.fda.gov/scripts/medwatch/  
All SAEs should simultaneously be faxed or e -mailed to BMS at:  
Global Pharmacovigilance & Epi[INVESTIGATOR_9611] -Myers Squibb Company  
Fax Number: 609 -818-3804 
Email: [EMAIL_178]  
• An SAE report should be completed for any event where doubt exists rega rding its 
seriousness.  
• For studies with long- term follow -up periods in which safety data are being reported, 
include the timing of SAE collection in the protocol.  
• If the investigator believes that an SAE is not related to study drug, but is potentially related to the conditions of the study (such as withdrawal of previous therapy or a 
complication of a study procedure), the relationship should be specified in the narrative section of the SAE Report Form.  
• If only limited information is initially available, follow -up reports are required. (Note: 
Follow -up SAE reports should include the same investigator term(s) initially reported.)  
• If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes available, a follow -up SAE report should be sent within [ADDRESS_700133] learning of the event.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 75 of 124  
 8.4.6  Reporting of Pregnancy  
• Women of childbearing potential” is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as [ADDRESS_700134] a documented serum follicle stimulating hormone (FSH) level more  than 40 mIU/ml.  
• Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 
weeks (30 days plus the time required for nivolumab to undergo five half -lives) after the 
last dose of investigational drug  
• Women of childbearing potential must have a negative serum or urine pregnancy test 
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 21  days prior to the start 
of nivolumab 
• Women must not be breastfeeding 
• Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men r eceiving nivolumab and who are sexually 
active with WOCBP will be instructed to adhere to contraception for a period of [ADDRESS_700135] Women who are not of childbearing potential (i.e., who are postmenopausal or sur gically sterile as well as azoospermic men 
do not require contraception 
• Should a woman be found to be pregnant during the study further treatment will be immediately discontinued. Permission from the patient will be sought to continue to assess her for adv erse events and for fetal outcomes.  
8.[ADDRESS_700136] be captured as appropriate  
• any laboratory test result that is clinically significant or meets the definition of an SAE  
• any laboratory test result abnormality that required the subject to have study drug 
discontinued or interrupted 
• any laboratory test result that required the subject to receive specific corrective therapy  
• It is expected that wherever possible the clinical rather than laboratory term would be used by [CONTACT_9673]  
8.6 Overdose  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700137] be 
reported as an SAE.  
Any such events will be recorded on an SAE form and reported to BMS within 24 hours/1 business day.  
Sub-site: If an overdose occurs, the sub -site must submit a completed FDA Medwatch 3500A 
Form and email form to the TJU study  site contact [CONTACT_537528].  
8.7 Potential Drug Induced Liver Injury (DILI) 
Wherever possible, timely confirmation of initial liver -related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs.  
Potential drug induced liver injury is defined as:  
• AT (ALT or AST) elevation > 3 times upper limit of normal (ULN) AND  
• Total bilirubin > [ADDRESS_700138], without initial findings of cholestasi s (elevated serum 
alkaline phosphatase), AND  
• No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, pre -existing chronic or acute liver disease, or 
the administration of other d rug(s) known to be hepatotoxic.  
8.8 Halting Rules  
Please see Section 11.3 for stoppi[INVESTIGATOR_004].  
9 Study Oversight  
In addition to the PI’s responsibility for oversight, study oversight will be under the direction of the SKCC’s Data and Safety Monitoring Committee ( DSMC). The SKCC DSMC operates in 
compliance with a Data and Safety Monitoring Plan (DSMP) that is approved by [CONTACT_6812] . 
10 Clinical Site Monitoring and Auditing 
Clinical site monitoring  and auditing is conducted to ensure that the rights of human participant s 
are protected, that the study is implemented in accordance with the protocol and/or other operating procedures, and that the quality and integrity of study data and data coll ection 
methods are maintained. Monitoring  and auditing for this study will be perf ormed in accordance 
with the SKCC’s Data and Safety Monitoring Plan ( DSMP) developed by [CONTACT_425584] (DSMC) . The DS MP specifies  the frequency of monitoring, 
monitoring procedures, the level of clinical site monitoring activ ities (e.g., the percentage of 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 77 of 124  
 participant  data to be reviewed), and the distribution of monitoring reports. Some monitoring 
activities may be performed remotely, while others will take place at the study site(s) . 
Appropriate staff will conduct monitoring activities and provide reports of the findings and 
associated action items in accordance with the  details described in the SKCC DSMP. 
11 Statistical  Considerations  
11.1 Study Hypotheses  
Our hypothesis is that in patients with newly diagnosed, previously untreated squamous cell 
carcinoma of the head and neck, the administration of nivolumab in combination with weekly 
carboplatin and paclitaxel will increase the pathological complete response rate at the primary 
cancer compared to the historical control of carboplat in and paclitaxel alone.  
11.2 Analysis Plans  
Primary Endpoint Evaluation:  
An optimal Simon two- stage design will be used. The null hypothesis is that the true pathologic 
complete response rate is ≤ 0.[ADDRESS_700139] the alternative that it is >0.20. After testing the regimen on [ADDRESS_700140] a pCR of the primary tumor. If the trial goes on to the second stage, a total of 37 patients will be 
studied. If the total number having a pCR of the primary tumor is less than or equal to 10, the 
regimen is rejected. This design yields a type I error rate of 9.5% and power of 90% when the 
true response rate is 0.40.  It has a 55% probability of stoppi[INVESTIGATOR_4428]. The pathologic complete 
response rate and its associated score 95% confidence interval will be estimated using the methods of Tsai et al (2008). 
20  
Secondary Endpoint Analyses:  
Descriptive statistics, including means, standard deviations, medians, quartiles, frequency 
counts, and percentages will be computed for all study variables.   
All secondary response rates (complete pathologic response at all sites of disease, major 
pathol ogic response at primary site, overall clinical response, clinical complete response) will be 
estimated.   
Kaplan- Meier methods will be used to describe and display the survival experiences of the study 
patients and estimate their 1 year PFS and assess their overall survival at 1 year.  
Exploratory Endpoint Analyses (CORRELATIVE STUDIES):  
T cell subsets will be analyzed by [CONTACT_537529], at the 5th week, and on the day of 
surgery after carboplatin/paclitaxel/nivolumab to explore their potential as predictive and/or 
prognostic markers that are related to response or clinical benefit of this induction regimen.   
The T cell subtypes will be analyzed from peripheral mononuclear cells (PBMC) via flow 
cytometry. These data and other biomarkers, including cytokine and exosome variables, will be 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700141] categorizing the before and after carboplatin/paclitaxel/nivolumab T cell data as 
well as the change observed and then using these categories as strata for cross -tabulation with 
complete pathologic response and for Kaplan- Meier subgroup analyses of the survival 
endpoints.  
Association of PDL1 expression and other baseline marker levels with response will be 
evaluated using logistic regression.  Association of change in markers with response will be 
evaluated using two- sample tests (e.g., t -tests or Wilcoxon rank sum tests).  When longitudinal 
marker measurements are available, responders will be compared to non- responders using 
mixed effects linear regression.  In addition, potential correlations of t hese pharmacodynamics 
markers with the duration of treatment, safety, survival, and anti -tumor activity of the regimen 
will be explored by [CONTACT_148216], data plots, and regression modeling tools.   
We plan to conduct descriptive statistics on all study variable, including PROs, lab data, 
demographics, and anthropometrics using standard statistics such as frequency tables, means, and standard deviations.  
 
 
For the correlative studies on PROs and metabolic measures (e.g., CRP, HbA1c, and lipid panel), we plan to estimate Spearman’s ranks -based correlations and explore 
multivariable relationships with ordinary least squares regression modeling. These variables will also be considered for their potential role in the planned Cox survival and logistic regre ssion response modeling.  
11.3 Interim Analyses and Stoppi[INVESTIGATOR_537494]:  
The study will stop for futility if pathologic complete response at the primary tumor is not 
observed in more than [ADDRESS_700142] 17 patients experience excessive toxicity due to study 
treatment, leading to delays in definitive surgery greater than 56 days from enrollment.  
11.3.1  Safety Review  
See above.in stoppi[INVESTIGATOR_004].  We meet weekly as a group to review adverse events on all trial 
patients.  A running tab is kept of the number of patients with serious adverse events and their grade, nature and attribution.
   
11.3.2  Efficacy Review  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700143] had their surgical specimens evaluable for pathologic response.  Accrual can then restart only if there are 3 or more pC Rs as 
per the stoppi[INVESTIGATOR_004].
   
11.4 Sample Size Considerations  
An optimal Simon two- stage design will be used. The null hypothesis is that the true pathologic 
complete response rate at the primary site is ≤ 0.[ADDRESS_700144] the alternative that it is >0.20. After testing the regimen on [ADDRESS_700145] stage, the trial will be 
terminated if 3 or fewer respond. If the trial goes on to the second stage, a total of 37 patients will be studied. If the total number responding is less than or e qual to 10, the regimen is 
rejected. This design yields a type I error rate of 9.5% and power of 90% when the true 
response rate is 0.40. It has a 55 % probability of stoppi[INVESTIGATOR_4428].   
11.4.[ADDRESS_700146] surgery will be replaced on the study.  
11.4.2  Accrual Estimates  
We hope to enroll 37 participants onto this trial  and accrual is competitive across all sites.  
11.5 Exploratory Analysis 
Please see the attached laboratory manual  
12 Source Documents and Access to Source Data/Documents  
Study staff wil l maintain appropriate medical and research records for this study, in compliance 
with ICH E6, and regulatory and institutional requirements for the protection of confidentiality of 
participant  information . Study staff will permit authorized representatives of SKCC  and 
regulatory agencies to examine (and when required by [CONTACT_1289], to copy) research records for the purposes of quality assurance reviews, audits, and evaluation of the study 
safety, progres s and data validity.   
13 Quality Control and Quality  Assurance  
The investigator will allocate adequate time for monitoring activities. The Investigator will also ensure that the medical monitor or other compliance or quality assurance reviewer is given 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 80 of 124  
 access to all of the  above  noted  study -related  documents  and  study  related  facilities  (e.g. 
pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.  
14 Ethics/Protection of Human Participant s  
14.[ADDRESS_700147]  
The inv estigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research, as drafted by [CONTACT_287531] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6.  
14.[ADDRESS_700148]  
The protocol, informed consent form(s), recruitment materials, and all participant  materials w ill 
be submitted to the IRB for review and approval.  Approval of both the protocol and the consent 
form must be obtained before any participant  is enrolled. Any amendment to the protocol will 
require review and approval by [CONTACT_537530] .  
14.[ADDRESS_700149].   
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
Pregnant and breastfeeding women are excluded from this tr ial due to the nature of the agents 
being used.  Otherwise, we will attempt to accrue women and men equally on this study, 
representative of the epi[INVESTIGATOR_537495].  
14.5 Participant Confidentiality  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700150] by [CONTACT_473], study staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 
samples and genetic tests in addition to any study information relating to participants.  
The study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor or other authorized representatives of the sponsor may inspect all study 
documents and records required to be maintained by [CONTACT_093], including but not limited 
to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the study participants. Th e clinical study site 
will permit access to such records.  
14.[ADDRESS_700151] eteness, legibility, and 
timeliness of the data reported. All source documents should be completed in a neat, legible 
manner to ensure accurate interpretation of data. The investigators will maintain adequate case 
histories of study participants, including  accurate case report forms (CRFs), and source 
documentation.  
15.[ADDRESS_700152] protected firewall - RedCap.  Each site will enter data as 
described into the electronic database. The lead site (Thomas Jefferson University) will query 
the database at regular intervals.  
15.3 Types of Data  
Data that will be collected include patient history and physical examination data, safety, laboratory studies, patient reported outcomes, pathology staging studies, and 
immunohistochemistry as determined in the laboratory.  
15.4 Study Records Retention  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700153] three years from the date that the grant federal 
financial report (FFR) is submitted to the NIH.  
Study documents should be retained for a minimum of [ADDRESS_700154] with this study (patent ownership, royalties, or 
financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict 
reviewed by a properly constituted Conflict of Interest Committee with a Committee- sanctioned 
conflict management plan that has been reviewed and approved by [CONTACT_28833]. All Jefferson University Investigators will follow the TJU Conflicts of Interest Policy for Employees (107.03).  
16.3 Participant Stipends or Payments  
Subjects will receive a payment of $[ADDRESS_700155].  
17 Publication and Data Sharing Policy  
This study will comply with the NIH Public Access Policy , which ensures that the public has 
access to the published results of NIH funded research. It requires scientists to submit final 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 83 of 124  
 peer-reviewed journal manuscripts that arise fro m NIH funds to the digital archive PubMed 
Central  upon acceptance for publication.  
The International Committee  of Medical Journal Editors (ICMJE) member journals have adopted 
a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial 
as any research project that prospectively assigns human participant s to intervention or 
concurrent comparison or control groups to study the cause -and-effect relationship between a 
medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health 
outcomes include any biomedical or health- related measures obtained in patients or 
participants, including pharmacokinetic measures and adverse events. The ICMJE policy requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov
, 
which is spons ored by [CONTACT_1055]. Other biomedical journals are 
considering adopting similar policies. T he ICMJE does not review specific studies to determine 
whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to publish.  
U.S. Public Law 110 -85 (Food and Drug Administration Amendments Act of 2007 or FDAAA), 
Title VIII, Section 801 mandates that a "responsible party" (i.e., the sponsor or designated 
principal investigator) register and report results of certain "applicable clinical trials:"  
Trials of Drugs and Biologics:  Controlled, clinical investigations, other than Phase I 
investigations, of a product subject to FDA regulation;  
Trials of Devices:  Controlled trials with health outcomes of a product subject  to FDA regulation 
(other than small feasibility studies) and pediatric postmarket surveillance studies.  
NIH grantees must take specific steps to ensure compliance  with NIH implementation of 
FDAAA.  
18 Literature References  
1. Cancer Facts & Figures 2016. (n.d.). Retrieved February 09, 2017, from 
https://www.cancer.org/research/cancer -facts- statistics/all -cancer -facts -figures/cancer -
facts -figures -2016.html  
2. Pfister DG, Spencer S, Brazil DM, et al. Head and neck cancers, Version 2.2014.  Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer 
Network: JNCCN. 2014; 12:1454- 87.  
3. Pulte D, Brenner H. Changes in survival in head and neck cancer in the late 20th and early 21st century: a period analysis. Oncologist, 2010;15:994 -1001  
4. Zhong LP, Zhang CP, Guo- Xin R, et al. Long -term results of a randomized phase III trial 
of TPF induction chemotherapy followed by [CONTACT_537531]. Oncotarget, 2013;6:[ZIP_CODE]- 714. 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 84 of 124  
 5. Licitra, L., Grandi, C., Guzzo, M., Mariani, L., Vullo, S. L., Valvo, F., ... & Cantù, G. 
(2003). Primary chemotherapy in resectable oral cavity squamous cell cancer: a 
randomized controlled trial . Journal of Clinical Oncology , 21(2), 327 -333. 
6.  Bossi P, Lo Villa S, Gusto M, et al. Preoperative chemotherapy in advanced resectable 
OCSCC: long -term results of a randomized phase III trial. Annals of Onc. 2014;25:426 -
466. 
7. Pi[INVESTIGATOR_119603], J.P., et al., Meta -analysis of chemotherapy in head and neck cancer (MACH -
NC): an update on 93 randomised trials and 17,346 patients.  Radiother Oncol, 2009. 
92(1): p. 4 -14. 
8. Gillison M, et al.; oral presentation at AACR Annual Meeting 2016; New Orleans, LA 3,4. 
At the 2016 AACR Annual Meeting  
9. Ferris, R. L., Blumenschein Jr, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., ... & 
Worden, F. (2016). Nivolumab for recurrent squamous -cell carcinoma of the head and 
neck. N Engl J Med , 2016(375), 1856 -1867.  
10. Herman LC, Chen L, Garnett A, et al. Comparison of carboplatin -paclitaxel to docetaxel -
cisplatin -5-flurouracil induction chemotherapy followed by [CONTACT_537532]. Oral Onc. 2014;50:52 -58. 
11.  Kies M, Holisnger C, Lee JJ, et al . Induction chemotherapy and cetuximab for locally 
advanced squamous cell carcinoma of the head and neck: results from a phase II 
prospective trial.  J Clin Oncol, 2010;28:8- 14. 
12. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for 
treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KENOTE- 012): an open label, multicenter, phase 1b trial. Lancet Oncol, 2016;7:[ADDRESS_700156]: the immunogenic eff ects of 
platinum -based chemotherapeutics. Clin Cancer Res, 2014;20:2831 -7. 
14. Lancer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non -squamous non- small- cell lung cancer: a randomized, 
phase 2 cohor t of the open- label KEYNOTE -021 study. Lancet Oncol, 2016;Oct 10 
(Epub ahead of print).  
15. Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum -
based doublet chemotherapy for first -line treatment of advanced non -small -cell lung 
cancer. J Clin Oncol;34:2969- 79. 
16. Kazandjian, D., Khozin, S., Blumenthal, G., Zhang, L., Tang, S., Libeg, M., ... & Pazdur, 
R. (2016). Benefit -risk summary of nivolumab for patients with metastatic squamous cell 
lung cancer after platinum -based chemotherapy: a report from the US Food and Drug 
Administration. JAMA oncology , 2(1), 118 -122.  
17. Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head 
and Neck Carcinoma (CheckMate 141). (n.d.). Retrieved February 09, 2017, from 
https://cl inicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700157] -Line Treatment of Advanced Non- Small- Cell Lung Cancer.  J Clin 
Oncol, 2016.  
19. Gadgeel, S. M., Stevenson, J., Langer, C. J., Gandhi, L., Borghaei, H., & Patnaik, A. 
(2016). Pembrolizumab (pembro) plus chemotherapy as front -line therapy for advanced 
NSCLC: KEYNOTE -021 cohorts AC. In Proc Am Soc Clin Oncol  (Vol. 34).  
20. Tsai WY, Chi Y, Ch en CM. Interval estimation of binomial proportion in clinical trials with 
a two -stage design.   Stat Med. 2008 Jan 15;27(1):15 -35.   
21. Lipscomb, J., C.C. Gotay, and C.F. Snyder, Patient -reported outcomes in cancer: 
a review of recent research and policy init iatives.  CA Cancer J Clin, 2007. 57 (5): 
p. 278- 300. 
22. Cella, D.F., et al., The Functional Assessment of Cancer Therapy scale: 
development and validation of the general measure.  J Clin Oncol, 1993. 11(3): p. 
570-9. 
23. Massie, M.J., Prevalence of depression in patients with cancer.  J Natl Cancer 
Inst Monogr, 2004(32): p. 57- 71. 
24. Currier, M.B. and C.B. Nemeroff, Depression as a risk factor for cancer: from pathophysiological advances to treatment implications.  Annu Rev Med, 2014. 65 : 
p. 203- 21. 
25. Mitchell, A.J., et al ., Prevalence of depression, anxiety, and adjustment disorder 
in oncological, haematological, and palliative- care settings: a meta- analysis of 94 
interview -based studies.  The Lancet Oncology. 12(2): p. 160- 174. 
26. Spi[INVESTIGATOR_16614], D. and J. Giese- Davis, Depression and cancer: mechanisms and 
disease progression.  Biol Psychiatry, 2003. 54(3): p. 269- 82. 
27. Gilbody, S., et al., Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta- analysis.  J Gen Intern Med, 
2007. 22(11): p. 1596 -602. 
28. Kroenke, K., R.L. Spi[INVESTIGATOR_626], and J.B. Williams, The PHQ -9: validity of a brief 
depression severity measure.  J Gen Intern Med, 2001. 16(9): p. 606- 13. 
29. Morley, J.J. and I. Kushner, Serum C
‐reactive protein levels in disease.  Annals 
of the New Yo rk Academy of Sciences, 1982. 389(1): p. 406- 418. 
30. Pepys, M.B. and G.M. Hirschfield, C-reactive protein: a critical update.  Journal of 
Clinical Investigation, 2003. 111 (12): p. 1805.  
31. Brustugun, O.T., M. Sprauten, and A. Helland, C -reactive protein (CRP) as a 
predictive marker for immunotherapy in lung cancer . 2016, American Society of 
Clinical Oncology.  
32. Shrotriya, S., et al., C -reactive protein is an important biomarker for prognosis 
tumor recurrence and treatment response in adult solid tumors: a systematic  
review.  PloS one, 2015. 10(12): p. e0143080.  
33. Godwin, J.L., et al., Nivolumab- induced autoimmune diabetes mellitus presenting 
as diabetic ketoacidosis in a patient with metastatic lung cancer.  Journal for 
immunotherapy of cancer, 2017. 5(1): p. 40.  
34. Okamoto , M., et al., Fulminant type 1 diabetes mellitus with anti ‐programmed 
cell death ‐1 therapy.  Journal of diabetes investigation, 2016. 7 (6): p. 915- 918. 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 86 of 124  
 35. Merino, S.M., et al., Lipid metabolism and lung cancer.  Critical reviews in 
oncology/hematology, 2017. 11 2: p. 31.  
36. Beloribi -Djefaflia, S., S. Vasseur, and F. Guillaumond, Lipid metabolic 
reprogramming in cancer cells.  Oncogenesis, 2016. 5(1): p. e189.  
37. Sokol, A., et al., Association between the dietary inflammatory index, waist -to-hip 
ratio and metabolic syndr ome.  Nutrition research, 2016. 36 (11): p. 1298- 1303.  
38. Cerhan, J.R., et al. A pooled analysis of waist circumference and mortality in 
650,000 adults . in Mayo Clinic proceedings . 2014. Elsevier.  
 
  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 87 of 124  
 Appendices  
Appendix A: Schedule of Events  
Appendix B: ECOG Performance Status  
Appendix C: AJCC 8th Edition Staging System  
Appendix D: Management of Algorithms  
Appendix E: NCI -PRO -CTCAE Items  
Appendix F: Sub -Site Unanticipated Problems Form  
Appendix G: Sub- Site Serious Adverse Event Form  
 
  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 88 of 124  
 APPENDIX A: SCHEDULE OF  EVENTS  
Study Period  Visit 1, 
Day 0 
(Baseline)  Treatment  Observation 
(d) 
Week   1 2 3 4 5 6 8 9  
Treatment   Paclitaxel+Carboplatin 
+ Nivolumab   Surgery   
Standard of 
care (d)  
Nivolumab   X  X  X     
Paclitaxel   X X X X X X    
Carboplatin   X X X X X X    
Filgrastim (i)   X X X X X X    
Consent form 
signed by 
[CONTACT_4676]  X          
Biopsy/Marking 
of primary site  X       X (f,g)    
History and 
physical exam 
(including vital 
signs, weight, BMI, height)  
(p) X(s) X  X  X  X(s) X(s) X 
ECOG 
Performance Status  (p) X X  X  X  X  X 
Assessment of 
concurrent therapi[INVESTIGATOR_014]  (p) X X  X  X     X   
Tumor 
assessment by X X  X  X  X  X 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 89 of 124  
 physical exam  
with intent to 
be alert to signs of early 
failure of 
efficacy as per the judgement 
of treating 
physicians (p).  
PET/CT  X(r)         X (e)  
CT or MRI  X(r)       X   
CBC, 
differential, 
platelet count  
(j) X X X X X X X X  X 
CMP , (j)  X X X X X X X X  X 
magnesium, 
phosphate, 
Amylase, 
Lipase, LDH  
(k) X X  X  X  X   
PT/PTT  (l) X X      X   
C-reactive 
protein (CRP), 
HbA1c, and lipid panel * X       X X  
Endocrine 
(TSH, Free T4, 
Free T3, 
cortisol)  (m) X X  X  X  X  X 
Pregnancy test 
(women of childbearing 
potential) (o) X X   X   X      
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 90 of 124  
 EKG (n) X       X (h)    
Blood Draw for 
CTCs (q) X     X  X (b)  X(c) X(c) 
Adverse Event 
Assessment +  
PRO -CTCAE   X X X X X X X  X 
PROs *  X      X X  
Tumor Biopsy  
(a)  X  X  X   X   
*These procedures are only to be performed for patients enrolled at Thomas Jefferson University  
(a) Five cores or excisional specimen. Archival tissue within 3 months of study enrollment can be 
used. If recent tumor is unavailable, a fresh biopsy will be taken prior to enrollment (see section 
6.1). Optional biopsies from and including days 14 to 23 will be done if patients agree to the 
collection and if feasible at the discretio n of the physician.  
(b) Prior to surgery  
(c) At least a week after surgery and less than [ADDRESS_700158] blood draw 2 months after  
(d) Observation or further therapy (for example post -operative radiation) as per standard of care.  
Follow for adverse events at least until 8  months s/p day 1 of induction therapy.  
(e) Timing of first post -operative repeat  as per standard of care.  For patients who will not have post -
op xrt, the PET/CT will be 3 months ±  [ADDRESS_700159] -op xrt, 
the PET/CT will be 3 months ± 2 weeks after the completion of xrt.  Further imaging (standard of 
care imaging will not be repeat PET/CT at this timepoint) will be another 3 months ±2 weeks after 
the follow -up PET/CT.   
(f) Intraoperative specimens sent fresh on ice for correlative studies.  
(g) Formal assessment and documentation of degree of pathologic response (as in appendix)  
(h) EKG alone  
(i) Filgrastim , at physician’s discretion, any 2 consecutive days between days 2- 6 (preferred days 
3,4) of each treatment week  
(j) CBC with differential, CMP,  need to be done baseline (within 14 days of initiation of study 
treatment  ), within [ADDRESS_700160] dose of chemotherapy, and no more than 1 days before each 
weekly chemotherapy administration.  No more than 7 days before surgery.    
(k) Magnesium, phosphate , amylase, lipase, and LDH  baseline (within 4 weeks of screening) , weeks 
3 and 5.  No more than 7 days before surgery.  
(l) PT/PTT baseline (within 4 weeks of screening) No more than 7 days before surgery.  
(m) Endocrine (TSH, Free T4, Free T3, cortisol, baseline (with in 4 weeks of screening) .  Again at 
week s [ADDRESS_700161] of care.  
(n) EKG:  baseline ( within 4 weeks of study enrollment ) and after last dose of chemo and before 
surgery.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 91 of 124  
 (o) Pregnancy test  at baseline must be within [ADDRESS_700162] be 
re-tested within 24 hours of start of study drug.  
(p) Must be done within 4 weeks of study enrollment  and then during visits 2, 3, 4, end of study visit  
(q) Must be done within 2 weeks of study enrollment  
(r) If patient cannot have PET/CT, then a CT or MRI of the Head and/or Neck, Chest, Abdomen, and 
Pelvis and a bone scan must be performed.  
(s) For patients enrolled at Thomas Jefferson University only: Physical examination at baseline and 
end of treatment must include BMI and waist to hip ratio (WHR)  
 
 
  
 
 
 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 92 of 124  
  
 
APPENDIX B: ECOG PERFORMANCE STATUS  
Grade  ECOG  
0 Fully active, able to carry on all pre- disease performance without 
restriction  
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5 Dead  
 
     
 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 93 of 124  
  
  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 94 of 124  
  
APPENDIX C: AJCC 8TH EDITION STAGING SYSTEM  
1. LIP AND ORAL CAVITY  
DEFINITIONS  
Primary Tumor (T)  
TX Primary tumor cannot be assessed  
Tis Carcinoma in situ  
Tis Carcinoma in situ  
T1 Tumor <2 cm < 5 mm depth of invasion (DOI) (DOI is depth of invasion and not tumor 
thickness)  
T2 Tumor <2 cm DOI >5 mm and < 10 mm or tumor > 2cm but <4 cnm abd < 10 mm DOI  
T3 Tumor >4 cm or any tumor > 10 mm DOI  
T4 Moderately advanced or very advanced local disease 
T4a Moderately advanced local disease: (lip) tumor invades through corical bone orinvolves 
the inferior alveolar nearve, floor of mouth, or skin of face (ie, chin or nose); (oral cavidty) 
tumor invades adjacent structures only (eg, through corical bone of the mandible or 
maxilla, or involves the maxillary sinus or skin or the face); note that superficial erosion of 
bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4.  
T4b Very advanced local disease: tumor invades masticator space, pterygoid plates, or skull 
base and/or encases the internal carotid artery  
 Regional Lymph Nodes (N)  
Lip and Oral Cavity  Clinical  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700163] dimension and ENE negative3; or metastases in multiple ipsilateral lymph nodes, 
none larger  than [ADDRESS_700164] dimension and ENE -negative; or 
metastasis  in any lymph node(s) and clinically overt ENE -positive  
N3a Metastatis in a lymph node larger than [ADDRESS_700165] dimension and ENE -negative 
N3b Metastasis in any node(s) and clinically overt ENE -positive  
  Lip and Oral Cavity Pathologic  
NX Regional lymph nodes cannot be assessed  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700166] dimension and ENE -
positive; or more than [ADDRESS_700167] dimension and ENE -
negative; or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in 
greater dimension and ENE -negative; or metastasis in bilateral or contralateral lymph 
nodes, none more than [ADDRESS_700168] 
dimension and E NE-positive; or metastasis in a single ipsilateral lymph node more than [ADDRESS_700169] dimension and ENE -negative; or 
metastasis  in a single ipsilateral lymph node more than [ADDRESS_700170] dimension and ENE-positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, 
with any ENE -positive  
N3a Metastasis in a single ipsilateral node more than [ADDRESS_700171] dimension and ENE -
positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, with 
any ENE -positive  
 
 Distant Metastasis (M)  
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
 Biopsy of metastatic site performed  
 Source of pathologic metastatic specimen  
 
 
 
Stage Groupi[INVESTIGATOR_007]  
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
IVA T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
 T2 N2 M0 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 96 of 124  
  T3 N2 M0 
 T4a N2  M0 
IVB Any T  N3 M0 
 T4b Any N  M0 
IVC Any T Any N M1  
 
Histologic Grade (G)  
GX Grade cannot be assessed 
G1 Well differentiated  
G2 Moderately differentiated  
G3 Poorly differentiated  
 
Residual Tumor (R)  
RX: Presence of residual tumor cannot be assessed 
R0: No residual tumor  
R1: Microscopic residual tumor  
R2: Macroscopic residual tumor  
 Additional Descriptors  
For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage groupi[INVESTIGATOR_007], they indicate cases 
needing separate analysis.  
m suffix  indicates the presence of multiple primary tumors in a single site and is recorded in 
parentheses: pT(m)NM.  
y prefix indicates those cases in which classification is performed during or following initial 
multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" 
categorization is not an estimate of tumor prior to multimodality therapy.  
r prefix  indicates a recurrent tumor when staged after a disease- free interval, and is identified 
by [CONTACT_941] "r" prefix: rTNM.  
a prefix designates the stage determi ned at autopsy: aTNM.  
  
 
2. PHARYNX (INCLUDING BASE OF TONGUE, SOFT PALATE, AND UVULA)  
DEFINITIONS  
 
 Oropharynx (HPV neg)  Clinical and Pathologic  
Tx Primary tumor cannot be assessed  
Tis Carcinoma in situ  
Tl Tumor [ADDRESS_700172] dimension or extension to lingual surface of epi[INVESTIGATOR_24050]  
T4 Moderatley advanced or very advanced local disease  
T4a Moderaly advanced local diseae; tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible (Mucosal extension to lingual surface of epi[INVESTIGATOR_537496] & Paclitaxel in SCCHN   Version 5.[ADDRESS_700173] itute invasion of the 
larynx).  
T4b Very advanced local disease; tumor invades lateral pterygoid muscle, pterygoid plates, lateral 
nasopharynx, or skull base or encases carotid artery  
 
Oropharynx (HPV pos) Clinical  and Pathologic  
T0 No primary identified 
Tl Tumor [ADDRESS_700174] dimension or extension to lingual surface of epi[INVESTIGATOR_24050]  
T4 Moderately advanced local disease: tumo r invades the larynx, extrinsic muscle of tongue, 
medial pterygoid, hard palate, or mandible or beyond*  
 
*  Mucosal extension to lingual surface of epi[INVESTIGATOR_537497].  
 
 
Regional Lymph Nodes (N)  
 Oropharynx (HPV neg) Clinical  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700175] dimension and ENE negative3; or metastases in multiple ipsilateral lymph nodes, 
none larger  than [ADDRESS_700176] dimension and ENE -negative; or 
metastasis  in any lymph node(s) and clinically overt ENE -positive  
N3a Metastatis in a lymph node larger than [ADDRESS_700177] dimension and ENE -negative 
N3b Metastasis  in any node(s) and clinically overt ENE -positive  
  
Oropharynx (HPV neg) Pathologic  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700178] dimension and ENE -
positive; or more than [ADDRESS_700179] dimension and ENE -
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 98 of 124  
 negative; or metastases in multiple ipsilateral lymph nodes, none mor e than 6 cm in 
greater dimension and ENE -negative; or metastasis in bilateral or contralateral lymph 
nodes, none more than [ADDRESS_700180] dimension, ENE -negative  
N2a Metastasis in a single ipsilateral or contralateral  lymph node 3 cm or less in greates t 
dimension and ENE -positive; or metastasis in a single ipsilateral lymph node more than [ADDRESS_700181] dimension and ENE -negative; or 
metastasis  in a single ipsilatera l lymph node more than [ADDRESS_700182] dimension and 
ENE-positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, 
with any ENE -positive  
N3a Metastas is in a single ipsilateral node more than [ADDRESS_700183] dimension and ENE -
positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, with 
any ENE -positive  
  
Oropharynx(HPV pos) Clinical   
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 One or more ipsilateral lymph nodes, none larger than 6cm  
N2 Contralateral or bilateral lymph nodes, none larger than 6cm  
N3 Metastasis in a lymph node more than [ADDRESS_700184] dimension  
 Distant Metastasis (M)  
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
 Biopsy of metastatic site performed  
 Source of pathologic metastatic specimen  
  
Stage Groupi[INVESTIGATOR_007]: Oropharynx (HPV neg)  
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
IVA T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 99 of 124  
  T2 N2 M0 
 T3 N2 M0 
 T4a N2 M0 
IVB T4b Any N  M0 
 Any T  N3 M0 
IVC Any T  Any N  M1 
 
 
Stage Groupi[INVESTIGATOR_007]: Oropharynx (HPV pos) Clinical  Stage 8th Edition Staging Manual  
 N0 N1 N2  N3 
T0 NA I II  III 
T1 I I II  III 
T2 I I II  III 
T3 II II II  III 
T4 III III III  III 
 
Any M1 is stage IV  
  
Histologic Grade (G) (Oropharynx)  
GX Grade cannot be assessed 
G1 Well differentiated  
G2 Moderately differentiated  
G3 Poorly differentiated  
 
Residual Tumor (R)  
RX Presence of residual tumor cannot be assessed  
R0 No residual tumor  
R1 Microscopic residual tumor  
R2 Macroscopic residual tumor  
 
Additional Descriptors  
For identification of special cases of TNM or pTNM classifications,  the "m" suffix and "y," "r," and 
"a" prefixes are used. Although they do not affect the stage groupi[INVESTIGATOR_007], they indicate cases 
needing separate analysis.  
m suffix  indicates the presence of multiple primary tumors in a single site and is recorded in 
parenthes es: pT(m)NM.  
y prefix indicates those cases in which classification is performed during or following initial 
multimodality therapy.  
The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the 
extent of tumor actually present  at the time of that examination. The "y" categorization is not an 
estimate of tumor prior to multimodality therapy.  
r prefix  indicates a recurrent tumor when staged after a disease- free interval, and is identified 
by [CONTACT_941] "r" prefix: rTNM.  
a prefix designa tes the stage determined at autopsy: aTNM.  
 
 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700185] dimension or with fixation of hemilarynx  
T4a Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland,  esophagus or central 
compartment soft tissue(2) 
T4b Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal 
structures  
 Hypopharynx Clinical
 
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700186] dimension and ENE negative3; or metastases in multiple ipsilateral lymph nodes, 
none larger  than [ADDRESS_700187] dimension and ENE -negative; or 
metastasis  in any lymph node(s) and clinically overt ENE -positive  
N3a Metastatis in a lymph node larger than [ADDRESS_700188] dimension and ENE -negative 
N3b Metastasis in any node(s) and clinically overt ENE -positive  
  
Hyphopharynx Pathologic  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700189] dimension and ENE -
positive; or more than [ADDRESS_700190] dimension and ENE -
negative; or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in 
greater dimension and ENE -negative; or metastasis in bilateral or contralateral lymph 
nodes, none more than [ADDRESS_700191] 
dimension and ENE -positive; or metastasis in a single ipsilateral lymph node more than [ADDRESS_700192] dimension an ENE -negative  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700193] dimension and ENE -negative; or 
metastasis  in a single ipsilateral lymph node more than [ADDRESS_700194] dimension and 
ENE-positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, 
with any ENE -positive  
N3a Metastasis in a single ipsilateral node more than [ADDRESS_700195] dimension and ENE -
positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, with 
any ENE -positive  
  
Distant Metastasis (M)  
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
 Biopsy of metastatic site performed  
 Source of pathologic metastatic specimen  
 Stage Groupi[INVESTIGATOR_007]: Hypopharynx  
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
IVA T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a N2 M0 
IVB T4b Any N  M0 
 Any T  N3 M0 
IVC Any T  Any N  M1 
 
Histologic Grade (G) (Hypopharynx)  
GX Grade cannot be assessed 
G1 Well differentiated  
G2 Moderately differentiated  
G3 Poorly differentiated  
 
Residual Tumor (R)  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 102 of 124  
 RX Presence of residual tumor cannot be assessed  
R0 No residual tumor  
R1 Microscopic residual tumor  
R2 Macroscopic residual tumor  
 
Additional Descriptors  
For identific ation of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and 
"a" prefixes are used. Although they do not affect the stage groupi[INVESTIGATOR_007], they indicate cases 
needing separate analysis.  
m suffix  indicates the presence of multiple primar y tumors in a single site and is recorded in 
parentheses: pT(m)NM.  
y prefix indicates those cases in which classification is performed during or following initial 
multimodality therapy.  
The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the 
extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.  
r prefix  indicates a recurrent tumor when staged after a disease- free interval, and i s identified 
by [CONTACT_941] "r" prefix: rTNM.  
a prefix designates the stage determined at autopsy: aTNM.  
   
4. LARYNX  
DEFINITIONS  
Primary Tumor (T)  
TX Primary tumor cannot be assessed  
T0 No evidence of primary tumor  
Tis Carcinoma in situ  
 
Supraglottis  
T1 Tumor limited to one subsite of supraglottis with normal vocal cord mobility  
T2 Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of 
pyrifo rm sinus) without fixation of the larynx  
T3 Tumor limited to larynx with vocal cord fixation and/or invades any of the following: 
postcricoid area, pre -epi[INVESTIGATOR_537498], paraglottic space, and/or minor thyroid cartilage 
erosion (e.g., inner cortex)  
T4a Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or esophagus)  
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures  
 Glottis  
T1 Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with 
normal mobility  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700196]  
T1b Tumor involves both vocal cords  
T2 Tumor extends to supraglottis and/or subglottis, or with impaired vocal cord mobility  
T3 Tumor limited to the larynx with vocal cord fixation, and/or invades paraglottic space, 
and/or minor thyroid cartilage erosion (e.g., inner cortex)  
T4a Tumor invades through the thyroi d cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)  
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediasti nal 
structures  
 
Subglottis  
T1 Tumor limited to the subglottis  
T2 Tumor extends to vocal cord(s) with normal or impaired mobility  
T3 Tumor limited to larynx with vocal cord fixation 
T4a Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, 
thyroid, or esophagus)  
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures  
  
Regional Lymph Nodes ( N) 
Larynx Clinical  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, [ADDRESS_700197] dimension and ENE negative3; or metastases in multiple ipsilateral lymph nodes, 
none larger  than [ADDRESS_700198] dimension and ENE -negative; or 
metastasis  in any lymph node(s) and clinically overt ENE -positive  
N3a Metastatis in a lymph node larger than [ADDRESS_700199] dimension and ENE -negative 
N3b Metastasis in any node(s) and clinically overt ENE -positive  
  
Larnynx Pathologic  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700200] dimension and ENE -
positive; or more than [ADDRESS_700201] dimension and ENE -
negative; or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in 
greater dimension and ENE -negative; or metastasis in bilateral or contralateral lymph 
nodes, none more than [ADDRESS_700202] 
dimension and ENE -positive; or metastasis in a single ipsilateral lymph node more than [ADDRESS_700203] dimension and ENE -negative; or 
metastasis  in a single ipsilateral lymph node more than [ADDRESS_700204] dimension and ENE-positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, 
with any ENE -positive  
N3a Metastasis in a single ipsilateral node more than [ADDRESS_700205]  dimension and ENE -
positive; or metastasis in multiple ipsilateral, contralateral, or bilateral lymph nodes, with 
any ENE -positive  
  Distant Metastasis (M)  
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
 Biopsy of metastatic site performed  
 Source of pathologic metastatic specimen  
 Stage Groupi[INVESTIGATOR_007]  
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
IVA T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a N2  M0 
IVB T4b Any N  M0 
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 105 of 124  
  Any T  N3 M0 
IVC Any T  Any N  M1 
 
Histologic Grade (G)  
GX Grade cannot be assessed 
G1 Well differentiated  
G2 Moderately differentiated  
G3 Poorly differentiated  
  
Residual Tumor (R)  
RX Presence of residual tumor cannot be assessed  
R0 No residual tumor  
R1 Microscopic r esidual tumor  
R2 Macroscopic residual tumor  
 
Additional Descriptors  
For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and 
"a" prefixes are used. Although they do not affect the stage groupi[INVESTIGATOR_007], they indicate cases 
needing separate analysis.  
m suffix  indicates the presence of multiple primary tumors in a single site and is recorded in 
parentheses: pT(m)NM.  
y prefix indicates those cases in which classification is performed during or following initial 
multimodalit y therapy.  
The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the 
extent of tumor actually present at the time of that examination. The "y" categorization is not an 
estimate of tumor prior to multimodality therapy.  
r prefix indicates a recurrent tumor when staged after a disease- free interval, and is identified 
by [CONTACT_941] "r" prefix: rTNM.  
a prefix designates the stage determined at autopsy: Atnm  
 
 
  
 
APPENDIX D: MANAGEMENT ALGORITHMS  
These general guidelines constitute guidance to the Investigator and may be 
supplemented by [CONTACT_537533]. The 
guidance applies to all immuno- oncology agents and regimens.  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.[ADDRESS_700206], especially prior to an invasive diagnostic or therapeutic procedure, is recommended.  
The frequency and severity of the related adverse events covered by [CONTACT_70744]- oncology agent or regimen being used.  
 
           
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 107 of 124  
 GI Adverse Event Mana geme nt Algorithm  
Rule  out non -inflamm atory causes. If  non-inflamm atory cause is  identified, treat accordingly  and continue I -O therapy. Opi[INVESTIGATOR_858]/na rcotics m ay mask  
symptoms of perforation. Infliximab should  not be  used in c ases of perforation or sepsis.  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 108 of 124  
 Renal  Adverse Event Mana geme nt Algorithm  
Rule  out non -inflamm atory causes. If  non-inflamm atory cause is  identified, treat accordingly  and continue I -O therapy 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 109 of 124  
 Pulmonary  Adverse Event Mana geme nt Algorithm  
Rule  out non -inflamm atory causes. If  non-inflamm atory cause, t reat accordingly and  continue I -O the rapy. Evaluat e with imaging and pulmona ry 
consultation. 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 110 of 124  
 Hepatic  Adverse Event Mana geme nt Algorithm  
Rule  out non -inflamm atory causes. If  non-inflamm atory cause, t reat accordingly and  continue I -O the rapy. Consider imaging f or obstruction.  
 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 111 of 124  
 Endocrinopa thy Mana geme nt Algorithm  
Rule  out non -inflamm atory causes. If  non-inflamm atory cause, t reat accordingly and  continue  I-O therapy. Consider  visual field testing, endocrinology  
consultation,  and imaging. 
 
 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 112 of 124  
 Skin Adverse Event Mana geme nt Algorithm  
Rule  out non-inflamm atory causes.  If non-inflamm atory cause, t reat accordingly  and continue  I-O therapy. 
 
 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 113 of 124  
 Neurological Adverse Event Mana geme nt Algorithm  
Rule  out non-inflamm atory causes.  If non-inflamm atory cause, t reat accordingly  and continue  I-O therapy. 
 
 
 

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 114 of 124  
 APPENDIX E: NCI PRO -CTCAE ITEMS 
 
                     
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 115 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 116 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 117 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 118 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 119 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 120 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 121 of 124  
 APPENDIX F: SUB- SITE UNATICIPATED PROBLEM FORM  
 
                     
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 122 of 124  
  

Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 123 of 124  
 Appendix G: SUB- SITE SERIOUS ADVERSE EVENT FORM  
Nivolumab with Carboplatin & Paclitaxel in SCCHN   Version 5.0  
Protocol 17P.513   05 November 2019  
 
 
 
Based on SKCC Interventional Protocol Template v.20170209  page 124 of 124  
  
